<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1750-2659</journal-id><journal-id journal-id-type="publisher-id">IRV</journal-id><journal-title-group><journal-title>Influenza and Other Respiratory Viruses</journal-title></journal-title-group><issn pub-type="ppub">1750-2640</issn><issn pub-type="epub">1750-2659</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6928032</article-id><article-id pub-id-type="doi">10.1111/irv.12697</article-id><article-id pub-id-type="publisher-id">IRV12697</article-id><article-categories><subj-group subj-group-type="overline"><subject>Formal Systematic Review (Commissioned or Non&#x02010;commissioned)</subject></subj-group><subj-group subj-group-type="heading"><subject>Formal Systematic Review (Commissioned or Non&#x02010;commissioned)</subject></subj-group></article-categories><title-group><article-title>Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement</article-title><alt-title alt-title-type="left-running-head">KHALAJ&#x02010;HEDAYATI et al.</alt-title></title-group><contrib-group><contrib id="irv12697-cr-0001" contrib-type="author"><name><surname>Khalaj&#x02010;Hedayati</surname><given-names>Atin</given-names></name><xref ref-type="aff" rid="irv12697-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="irv12697-cr-0002" contrib-type="author"><name><surname>Chua</surname><given-names>Caroline Lin Lin</given-names></name><xref ref-type="aff" rid="irv12697-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="irv12697-cr-0003" contrib-type="author"><name><surname>Smooker</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="irv12697-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="irv12697-cr-0004" contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Khai Wooi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0775-0923</contrib-id><xref ref-type="aff" rid="irv12697-aff-0001">
<sup>1</sup>
</xref><address><email>khaiwooi.lee@taylors.edu.my</email><email>khaiwooilee@gmail.com</email></address></contrib></contrib-group><aff id="irv12697-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">School of Biosciences</named-content>
<named-content content-type="organisation-division">Faculty of Health and Medical Sciences</named-content>
<institution>Taylor's University</institution>
<city>Subang Jaya</city>
<country country="MY">Malaysia</country>
</aff><aff id="irv12697-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Biosciences and Food Technology</named-content>
<named-content content-type="organisation-division">School of Science</named-content>
<institution>RMIT University</institution>
<city>Bundoora</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Khai Wooi Lee, School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, No. 1, Jalan Taylor's, 47500 Subang Jaya, Selangor, Malaysia.<break/>
Emails: <email>khaiwooi.lee@taylors.edu.my</email>; <email>khaiwooilee@gmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2020</year></pub-date><volume>14</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/irv.v14.1</issue-id><fpage>92</fpage><lpage>101</lpage><history><date date-type="received"><day>02</day><month>5</month><year>2019</year></date><date date-type="rev-recd"><day>14</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>01</day><month>10</month><year>2019</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2019 The Authors. <italic>Influenza and Other Respiratory Viruses</italic> Published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:IRV-14-92.pdf"/><abstract id="irv12697-abs-0001"><title>Abstract</title><p>The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen&#x02010;presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen&#x02010;presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="irv12697-kwd-0001">immunogenicity</kwd><kwd id="irv12697-kwd-0002">influenza vaccine</kwd><kwd id="irv12697-kwd-0003">nanoparticles</kwd><kwd id="irv12697-kwd-0004">subunit vaccine</kwd><kwd id="irv12697-kwd-0005">vaccine delivery</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Taylor's Internal Research Grant Scheme &#x02010; Emerging Research Funding Scheme (TIRGS&#x02010;ERFS)</funding-source><award-id>TRGS/ERFS/1/2018/SBS/039</award-id></award-group><award-group id="funding-0002"><funding-source>Taylor's Internal Research Grant Scheme &#x02010; Major Funding Scheme (TIRGS&#x02010;MFS)</funding-source><award-id>TRGS/MFS/2/2013/SBS/001</award-id></award-group></funding-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="10"/><word-count count="8299"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.3 mode:remove_FC converted:23.12.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="irv12697-cit-1001">
<string-name>
<surname>Khalaj&#x02010;Hedayati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chua</surname>
<given-names>CLL</given-names>
</string-name>, <string-name>
<surname>Smooker</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KW</given-names>
</string-name>. <article-title>Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement</article-title>. <source xml:lang="en">Influenza Other Respi Viruses</source>. <year>2020</year>;<volume>14</volume>:<fpage>92</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12697</pub-id>
</mixed-citation>
</p><fn-group id="irv12697-ntgp-0001"><fn id="irv12697-note-0002"><p>The peer review history for this article is available at <ext-link ext-link-type="uri" xlink:href="https://publons.com/publon/10.1111/irv.12697">https://publons.com/publon/10.1111/irv.12697</ext-link>.</p></fn></fn-group></notes></front><body id="irv12697-body-0001"><sec id="irv12697-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Influenza virus infection is a global public health problem, causing a huge morbidity and mortality burden due to annual epidemics and pandemics. Worldwide, annual epidemics cause 3 to 5 million cases of severe illness, and about 290,000 to 650,000 deaths.<xref rid="irv12697-bib-0001" ref-type="ref">1</xref> Vaccination is the most effective method to prevent influenza infection. Current influenza vaccines mainly rely on hemagglutinin (HA) proteins as antigens to induce neutralizing antibodies that can inhibit virus infection and replication in humans. These antibodies are mostly targeting the immunodominant epitopes of the influenza virus that are highly variable between different virus strains. Each year, new variants of influenza virus may emerge due to antigenic drift, which necessitates the reformulation of influenza vaccines on a yearly basis.<xref rid="irv12697-bib-0002" ref-type="ref">2</xref> Previously, mismatches between predicted and actual circulating strain have resulted in reduced vaccine protection and increased clinical cases.<xref rid="irv12697-bib-0003" ref-type="ref">3</xref> A &#x0201c;universal&#x0201d; vaccine that targets the conserved regions of influenza viruses and induces a broadly protective immunity may dramatically improve protection against seasonal and pandemic influenza viruses. Antibodies that target conserved sites in the HA stalk have been isolated from humans and shown to confer protection in animals challenged with various influenza virus strains and subtypes.<xref rid="irv12697-bib-0004" ref-type="ref">4</xref> However, it is noteworthy that antibodies specifically targeting the conserved HA2 region can also increase disease severity by enhancing viral fusion to target cells, hence should be given sufficient consideration during universal vaccine design and evaluation.<xref rid="irv12697-bib-0005" ref-type="ref">5</xref>
</p><p>Licensed influenza vaccines are currently available as inactivated (whole inactivated virus vaccine, split virus vaccine or subunit vaccine), live attenuated, and recombinant vaccines (Table <xref rid="irv12697-tbl-0001" ref-type="table">1</xref>). These vaccines are produced in eggs or cell cultures and mainly induce antibodies against strain&#x02010;specific HA.<xref rid="irv12697-bib-0006" ref-type="ref">6</xref> Today, research is more focused on the development of subunit vaccines, as they are safer and easier to produce. With recombinant technology, the production of epitopes of interest, such as the conserved stalk domain of HA, can be done. In addition to vaccine antigens, adjuvants are also sometimes added to vaccines to boost immunogenicity. Adjuvants are particularly important in the development of influenza vaccines for the elderly population who has decreased immune capacity and during pandemics, where a rapid antibody response is required.<xref rid="irv12697-bib-0007" ref-type="ref">7</xref> In addition, adjuvants are also required in the development of novel peptide&#x02010;based influenza vaccines, which are known to have low immunogenicity. There are currently six types of adjuvants that have been included in licensed influenza vaccines; alum, AS03, AF03, MF59, heat labile enterotoxin, and virosome, which is a nanoparticle (NP).</p><table-wrap id="irv12697-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Currently available influenza vaccines for the 2019&#x02010;2020 influenza season in the United States<xref rid="irv12697-bib-0112" ref-type="ref">112</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Vaccines</th><th align="left" valign="top" rowspan="1" colspan="1">Manufacturers</th><th align="left" valign="top" rowspan="1" colspan="1">Production</th><th align="left" valign="top" rowspan="1" colspan="1">Preparation</th><th align="left" valign="top" rowspan="1" colspan="1">Type</th><th align="left" valign="top" rowspan="1" colspan="1">Adjuvant</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Afluria Quadrivalent</td><td align="left" rowspan="1" colspan="1">Seqirus Pty. Ltd.</td><td align="left" rowspan="1" colspan="1">Eggs</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">Split virus</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Fluad</td><td align="left" rowspan="1" colspan="1">Seqirus, Inc</td><td align="left" rowspan="1" colspan="1">Eggs</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">Purified subunit</td><td align="left" rowspan="1" colspan="1">MF59&#x000ae;</td></tr><tr><td align="left" rowspan="1" colspan="1">Fluarix Quadrivalent</td><td align="left" rowspan="1" colspan="1">GlaxoSmithKline Biologicals</td><td align="left" rowspan="1" colspan="1">Eggs</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">Split virus</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Flublok Quadrivalent</td><td align="left" rowspan="1" colspan="1">Protein Sciences Corporation</td><td align="left" rowspan="1" colspan="1">Insect cells</td><td align="left" rowspan="1" colspan="1">Recombinant</td><td align="left" rowspan="1" colspan="1">Subunit</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Flucelvax Quadrivalent</td><td align="left" rowspan="1" colspan="1">Seqirus, Inc</td><td align="left" rowspan="1" colspan="1">MDCK cells</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">Purified subunit</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">FluLaval Quadrivalent</td><td align="left" rowspan="1" colspan="1">ID Biomedical Corporation of Quebec</td><td align="left" rowspan="1" colspan="1">Eggs</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">Split virus</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">FluMist Quadrivalent</td><td align="left" rowspan="1" colspan="1">MedImmune, LLC</td><td align="left" rowspan="1" colspan="1">Eggs</td><td align="left" rowspan="1" colspan="1">Attenuated</td><td align="left" rowspan="1" colspan="1">Live virus</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Fluzone High Dose</td><td align="left" rowspan="1" colspan="1">Sanofi Pasteur, Inc</td><td align="left" rowspan="1" colspan="1">Eggs</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">Split virus</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">Fluzone Quadrivalent</td><td align="left" rowspan="1" colspan="1">Sanofi Pasteur, Inc</td><td align="left" rowspan="1" colspan="1">Eggs</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">Split virus</td><td align="left" rowspan="1" colspan="1">&#x02010;</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Recently, the potential use of NPs as adjuvants in vaccines has been gaining interest. The inclusion of NPs in vaccine formulations has been reported to enhance antigen stability,<xref rid="irv12697-bib-0008" ref-type="ref">8</xref>, <xref rid="irv12697-bib-0009" ref-type="ref">9</xref>, <xref rid="irv12697-bib-0010" ref-type="ref">10</xref> promote targeted antigen delivery,<xref rid="irv12697-bib-0011" ref-type="ref">11</xref>, <xref rid="irv12697-bib-0012" ref-type="ref">12</xref> and assist slow release of antigens <xref rid="irv12697-bib-0013" ref-type="ref">13</xref>, <xref rid="irv12697-bib-0014" ref-type="ref">14</xref> to eliminate the need for booster shots.<xref rid="irv12697-bib-0015" ref-type="ref">15</xref>, <xref rid="irv12697-bib-0016" ref-type="ref">16</xref> Different NPs have been evaluated for their ability to deliver antigens and increase immune responses against influenza antigens in vaccines. The current review focuses on the latest scientific advancement in the application of different NPs in influenza subunit vaccine development to enhance immunogenicity (Table <xref rid="irv12697-tbl-0002" ref-type="table">2</xref>).</p><table-wrap id="irv12697-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Current development of nanoparticle&#x02010;based influenza vaccines</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">NPs</th><th align="left" valign="top" rowspan="1" colspan="1">Vaccine candidate composition</th><th align="left" valign="top" rowspan="1" colspan="1">Humoral response</th><th align="left" valign="top" rowspan="1" colspan="1">Cellular response</th><th align="left" valign="top" rowspan="1" colspan="1">Cross&#x02010;protection</th><th align="left" valign="top" rowspan="1" colspan="1">Protective against lethal challenge</th><th align="left" valign="top" rowspan="1" colspan="1">Animal species</th><th align="left" valign="top" rowspan="1" colspan="1">Clinical phase</th><th align="left" valign="top" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Spore</td><td align="left" rowspan="1" colspan="1">CotB&#x02010;M2e3 (H1, H2, H3)</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0024" ref-type="ref">24</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x02010;S&#x02010;HA</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">Chicken</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0113" ref-type="ref">113</xref>
</td></tr><tr><td align="left" rowspan="9" colspan="1">VLP</td><td align="left" rowspan="1" colspan="1">BV VLP&#x02010;HA&#x02010;NA&#x02010;M1</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0038" ref-type="ref">38</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">BV VLP&#x02010;HA&#x02010;NA&#x02010;M1</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">Mice and ferrets</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0039" ref-type="ref">39</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HBc VLP&#x02010;M2e&#x02010;HA2 (Tandiflu1)</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0043" ref-type="ref">43</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HBc VLP&#x02010;M2e&#x02010;NP</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0044" ref-type="ref">44</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Influenza VLP&#x02010;HA (H1, H8, H13, H3, H4, H10)</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0114" ref-type="ref">114</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant A (H1N1) 2009 influenza VLP vaccine (HA)</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">Human</td><td align="left" rowspan="1" colspan="1">Phase II</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0046" ref-type="ref">46</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">gH1&#x02010;Qbeta (HA1)</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">Human</td><td align="left" rowspan="1" colspan="1">Phase I</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0061" ref-type="ref">61</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">A(H7N9) VLP Antigen (HA, NA, M1)</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">Human</td><td align="left" rowspan="1" colspan="1">Phase I</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0047" ref-type="ref">47</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Plant&#x02010;based QVLP (HA)</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">Human</td><td align="left" rowspan="1" colspan="1">Phase I &#x00026; II</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0115" ref-type="ref">115</xref>, <xref rid="irv12697-bib-0116" ref-type="ref">116</xref>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Phage VLP</td><td align="left" rowspan="1" colspan="1">T7&#x02010;M2e</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0058" ref-type="ref">58</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">QB&#x02010;M2e</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0060" ref-type="ref">60</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Polysaccharide</td><td align="left" rowspan="1" colspan="1">Chitosan&#x02010;DNA</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0008" ref-type="ref">8</xref>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Liposome</td><td align="left" rowspan="1" colspan="1">HA/DC&#x02010;Chol:DPPC liposomes</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0117" ref-type="ref">117</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Vaxfectin (TIV)</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0078" ref-type="ref">78</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Virosome</td><td align="left" rowspan="1" colspan="1">Inflexal V HA&#x02010;NA</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Human</td><td align="left" rowspan="1" colspan="1">FDA&#x02010;approved</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0087" ref-type="ref">87</xref>, <xref rid="irv12697-bib-0118" ref-type="ref">118</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ISCOM</td><td align="left" rowspan="1" colspan="1">Viral protein</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Phase I</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0097" ref-type="ref">97</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gold</td><td align="left" rowspan="1" colspan="1">Au&#x02010;HA</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">&#x0221a;</td><td align="left" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Pre&#x02010;clinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="irv12697-bib-0104" ref-type="ref">104</xref>
</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="irv12697-sec-0002"><label>2</label><title>NANOPARTICLES IN INFLUENZA VACCINE DEVELOPMENT</title><p>NPs are comparable to pathogens in terms of their size (1&#x02010;1000&#x000a0;nm), and thus, they can be efficiently recognized by immune cells and can therefore act as carriers to induce desirable immune&#x02010;activating effects. NPs can facilitate the delivery of loaded antigens to the primary antigen&#x02010;presenting cells (APCs).<xref rid="irv12697-bib-0017" ref-type="ref">17</xref>, <xref rid="irv12697-bib-0018" ref-type="ref">18</xref> For efficient protection against influenza, influenza vaccines are required to induce specific antibody responses, such as antibodies belonging primarily to the immunoglobulin G (IgG) subclass that can block the function of HA, either via blocking host receptor binding or preventing fusion.<xref rid="irv12697-bib-0019" ref-type="ref">19</xref>, <xref rid="irv12697-bib-0020" ref-type="ref">20</xref> To promote vaccine immunogenicity, various types of NPs have been employed in the design of influenza subunit vaccines such as bacterial spores, virus&#x02010;like particles (VLPs), bacteriophages, polysaccharides, liposomes, virosomes, immune&#x02010;stimulating complexes (ISCOM), and inorganic NPs, which are reviewed here under &#x0201c;Natural&#x0201d; and &#x0201c;Synthetic&#x0201d; nanoparticle categories.</p><sec id="irv12697-sec-0003"><label>2.1</label><title>Natural nanoparticles</title><sec id="irv12697-sec-0004"><label>2.1.1</label><title>Bacterial spore</title><p>Spores are quiescent cells that can be produced by certain bacterial species such as the Gram&#x02010;positive <italic>Bacilli</italic> and <italic>Clostridia</italic>.<xref rid="irv12697-bib-0021" ref-type="ref">21</xref> Spore formation is a survival strategy that enables the bacteria to survive in harsh environmental conditions. Typically, mature spores are 800&#x02010;1200&#x000a0;nm in size and have either a spherical or ellipsoidal shape.<xref rid="irv12697-bib-0022" ref-type="ref">22</xref> Interestingly, a spore can self&#x02010;assemble into its functional structure and when used as a vaccine carrier, it can protect the antigens on its surface from degradation and stimulate an immune response.<xref rid="irv12697-bib-0023" ref-type="ref">23</xref>, <xref rid="irv12697-bib-0024" ref-type="ref">24</xref> The spores of <italic>B&#x000a0;subtilis</italic> have high stability, low production cost, facile construction, and a good safety profile which earns them the Generally Recognized as Safe (GRAS) status.<xref rid="irv12697-bib-0025" ref-type="ref">25</xref> Moreover, they can be administered via the oral pathway, where they can protect the antigens from degradation by stomach acid prior to reaching immune cells within the small intestine.<xref rid="irv12697-bib-0026" ref-type="ref">26</xref> In vaccine design, these bacterial spores are usually conjugated to vaccine antigens through recombinant technology. However, for them to work efficiently, the vaccine antigens need to be of certain size and complexity to effectively activate antigen presentation.<xref rid="irv12697-bib-0027" ref-type="ref">27</xref> Apart from that, the possibilities of transferring selectable marker genes, and release of live recombinant bacterial spores, are major concerns. Recently, antigen co&#x02010;administration and antigen adsorption to non&#x02010;recombinant spores were reported as safer alternatives.<xref rid="irv12697-bib-0028" ref-type="ref">28</xref>, <xref rid="irv12697-bib-0029" ref-type="ref">29</xref>
</p><p>
<italic>Bacillus subtilis</italic> spores have been used in the design of an oral influenza vaccine, where the spore coat protein of <italic>B&#x000a0;subtilis</italic> PY79 (CotB) was fused with three copies of conserved matrix protein (M2e). M2e is the ectodomain of M2 protein, a proton channel of the influenza virus, that is highly conserved across all human influenza virus A strains, thus making it one of the main targets for universal influenza vaccine development. The authors reported that M2e was successfully displayed on the spore surface and the recombinant spore (RSM2e3) exhibited significant immunogenicity in mice. Repeated immunization was shown to elicit M2e&#x02010;specific IgG (titer of 1:12,800 at week 17 post&#x02010;1st immunization), as well as strong cellular immune responses. When immunized mice were further challenged with A/PR/8/34 (H1N1) influenza virus, lung specimens revealed significantly lower levels of the virus titers compared to the control group, in addition to a 100% survival rate.<xref rid="irv12697-bib-0024" ref-type="ref">24</xref> In a similar study, a tandem repeat of four consensus sequences coding for the human&#x02039;avian&#x02039;swine&#x02039;human M2e (M2eH&#x02010;A&#x02010;S&#x02010;H) peptide was fused to <italic>B&#x000a0;subtilis</italic> spore coat proteins and stably expressed on the spore surface. Oral immunization of mice with the recombinant spore carrying M2eH&#x02010;A&#x02010;S&#x02010;H was reported to elicit specific antibody production in the absence of any other adjuvant. However, the levels of antibody titers were relatively low, suggesting that the induced immunity was inadequate for protection and some modifications in vaccine preparation may be required to increase immunogenicity.<xref rid="irv12697-bib-0030" ref-type="ref">30</xref>
</p><p>Live and heat&#x02010;inactivated spores of <italic>B&#x000a0;subtilis</italic> can also be directly used in vaccine production due to their ability in binding to influenza virions. In a previous study, mice that were intranasally immunized with killed spores adsorbed to H5N1 virions&#x000a0;(NIBRG&#x02010;14) were fully protected even after being challenged with a lethal dose of the virus (&#x002c3;20 times LD<sub>50</sub>). Particularly interesting was the observation that in the absence of influenza antigens, the killed spores alone were able to confer about 60% partial protection in the animals, suggesting that the spores themselves are immunogenic in nature.<xref rid="irv12697-bib-0031" ref-type="ref">31</xref> This type of protection however was short&#x02010;lived and has been attributed to the recruitment of natural killer cells into lungs in response to the killed spores.</p></sec><sec id="irv12697-sec-0005"><label>2.1.2</label><title>Virus&#x02010;like particles</title><p>Virus&#x02010;like particles (VLPs) are self&#x02010;assembling and non&#x02010;replicating particles that are devoid of infectious genetic material.<xref rid="irv12697-bib-0032" ref-type="ref">32</xref> VLPs can be produced from different host cells, which include bacteria, yeast, insect, and animal cell lines. They can be used as both particulate carriers and immunopotentiators in vaccine development due to their immunogenic characteristics such as having similar size to original pathogen, repetitive surface geometry, and ability to induce innate and adaptive immune responses.<xref rid="irv12697-bib-0033" ref-type="ref">33</xref> The main advantage of VLP&#x02010;based vaccines is that the immune system of the host can recognize VLPs in a similar way to the original virus to promote a robust immune response.<xref rid="irv12697-bib-0034" ref-type="ref">34</xref> They have been primarily designed to promote B&#x02010;cell activation and induce potent antibody responses following activation of T helper cells.<xref rid="irv12697-bib-0035" ref-type="ref">35</xref>, <xref rid="irv12697-bib-0036" ref-type="ref">36</xref>
</p><p>There are several licensed human prophylactic VLP&#x02010;based vaccines such as Cervarix&#x000ae;, Gardasil&#x000ae;, and Gardasil9&#x000ae; against human papillomavirus (HPV) and the third generation Sci&#x02010;B&#x02010;Vac&#x02122; vaccine against hepatitis B virus (HBV). VLP&#x02010;based approaches are also explored as a promising approach for the development of a universal influenza vaccine.<xref rid="irv12697-bib-0037" ref-type="ref">37</xref> To design a successful VLP&#x02010;based vaccine, the most applicable VLP construct has to be selected and antigens need to be incorporated without destabilizing the VLPs. To achieve this, each biological virus&#x02010;derived particle needs to be studied in detail for their properties and possible side effects before use in human.</p><p>Virus&#x02010;like particle&#x02010;based vaccines have been widely explored in the design of influenza vaccines, with promising results in providing protection against the infection. An influenza VLP&#x02010;based vaccine candidate consisting of influenza HA, NA, and matrix protein (M1) (H7N9 A/Shanghai/2/2013) was reported to successfully elicit strong humoral and cellular immune responses in mice when administered either via the intramuscular (IM) or intranasal immunization routes. Notably, only 10&#x000a0;&#x003bc;g of H7N9 VLPs was required to achieve a 100% survival rate against a lethal dose of H7N9 virus.<xref rid="irv12697-bib-0038" ref-type="ref">38</xref> Another study reported that influenza H3N2&#x02010;VLPs expressing HA, NA, and M1 proteins induced protective antibody responses with higher efficacy and potency than the whole inactivated vaccines in mice and ferrets.<xref rid="irv12697-bib-0039" ref-type="ref">39</xref> M2e5x is another VLP&#x02010;based vaccine candidate that has been genetically engineered to contain a tandem repeat of five M2e variants from human, swine, and avian influenza A viruses. It was shown to protect infected mice against a lethal challenge from distinct influenza A viruses (H3N2 and H5N1).<xref rid="irv12697-bib-0040" ref-type="ref">40</xref>, <xref rid="irv12697-bib-0041" ref-type="ref">41</xref> Additionally, M2e5x was able to increase the immunogenicity of split vaccines and promote cross&#x02010;protection when tested in ferrets.<xref rid="irv12697-bib-0042" ref-type="ref">42</xref>
</p><p>Tandiflu1 is an influenza VLP&#x02010;based vaccine candidate comprising of a hepatitis B virus core (HBc) VLPs fused to four conserved antigens from M2e and HA stalk. Vaccination with Tandiflu1 led to the production of cross&#x02010;reactive and protective antibodies, which resulted in 100% protection from a lethal influenza challenge with H1N1 in mice. In addition, serum transfer from vaccinated animals successfully conferred protection from influenza&#x02010;associated illness in na&#x000ef;ve mice.<xref rid="irv12697-bib-0043" ref-type="ref">43</xref> A previous study which also similarly used HBc VLPs as carriers for three M2e protein and nucleoprotein (NP) epitopes was shown to induce potent humoral and cell&#x02010;mediated immunity in mice.<xref rid="irv12697-bib-0044" ref-type="ref">44</xref> A single vaccine shot that contains multiple VLPs against different virus subtypes can result in broad protection. Mice vaccinated with a mixture of influenza VLPs containing 4 different HA subtypes of influenza A viruses (H1, H3, H5, and H7) were protected from lethal challenges with same subtypes and also other hetero sub&#x02010;typic strains that were not included in the vaccine.<xref rid="irv12697-bib-0045" ref-type="ref">45</xref>
</p><p>A few VLP influenza vaccines have been tested in humans with promising results. For example, VLP vaccines against influenza A/California/04/2009 (H1N1) was tested in adults and showed good safety and immunogenicity profiles, where 82%&#x02010;92% of individuals who received a single dose of vaccine achieved &#x02265;40 hemagglutinin inhibition (HAI) titer.<xref rid="irv12697-bib-0046" ref-type="ref">46</xref> For the recombinant VLP influenza A (H7N9) vaccine, the presence of ISCOMATRIX&#x02122; adjuvant was needed to induce protective antibodies. In the phase I clinical trial, 80.6% of subjects receiving adjuvanted H7N9 VLP vaccine developed HAI responses compared to 15.6% in the group who received a higher dose of non&#x02010;adjuvanted vaccine.<xref rid="irv12697-bib-0047" ref-type="ref">47</xref> Nanoflu, which is a quadrivalent VLP vaccine with Matrix&#x02010;M adjuvant, was tested in older adults (&#x02265;65&#x000a0;years old) at phase 2 clinical trial and reported to induce significant HAI responses.<xref rid="irv12697-bib-0048" ref-type="ref">48</xref>, <xref rid="irv12697-bib-0049" ref-type="ref">49</xref> Recently, the Quadrivalent VLP Influenza Vaccine comprising of H1, H3, and two B hemagglutinin proteins is being tested in elderly adults at phase 3 clinical trial.<xref rid="irv12697-bib-0050" ref-type="ref">50</xref>
</p><p>Interestingly, VLPs can be modified via recombinant technology to contain additional adjuvant, such as bacterial proteins to further enhance immunogenicity. Wang et al studied the effect of adding a modified <italic>Salmonella</italic> flagellin protein to influenza VLPs associated with HA and M1 proteins. They reported that these chimeric VLPs induced higher IgG2a and IgG2b levels and cytokine responses when compared to control VLPs without the flagellin protein. The chimeric VLPs not only conferred full protection against the homologous PR8 virus strain, but it also showed significant cross&#x02010;protection by having a 67% survival rate when challenged with a lethal dose of heterosubtypic H3N2 strain.<xref rid="irv12697-bib-0034" ref-type="ref">34</xref> Results from a clinical study showed that the HA influenza&#x02010;flagellin recombinant vaccine (VAX125) was highly immunogenic in a group of elderly population (&#x02265;65&#x000a0;years old).<xref rid="irv12697-bib-0048" ref-type="ref">48</xref> Another influenza vaccine, STF2.4&#x000a0;&#x000d7;&#x000a0;M2e&#x000a0;(VAX102), which consists of <italic>Salmonella typhimurium</italic> flagellin type 2 protein fused to M2e protein was tested in healthy, young individuals and reported to be safe and immunogenic at low doses (0.3&#x02010;1.0&#x000a0;&#x003bc;g).<xref rid="irv12697-bib-0051" ref-type="ref">51</xref> However, at higher doses (3 and 10&#x000a0;&#x003bc;g), the vaccine was associated with severe symptoms due to increased levels of C&#x02010;reactive protein.</p></sec><sec id="irv12697-sec-0006"><label>2.1.3</label><title>Bacteriophage VLPs</title><p>Phage VLPs are not pathogenic, and there is no pre&#x02010;existing immunity against them in humans; consequently, they are safer than other VLPs.<xref rid="irv12697-bib-0052" ref-type="ref">52</xref> Barfoot et al showed that T4 phages can be taken up by DCs as efficiently as the influenza virus.<xref rid="irv12697-bib-0053" ref-type="ref">53</xref> Bacteriophage VLP systems employ phage capsid proteins to display peptides or proteins on the surface of the phage. The cargo size is usually dependent on the types of phage. For example, bacteriophage T7 capsid proteins 10A and 10B can accommodate about 400 copies of peptide or protein with 50&#x02010;1200 amino acids. Gene VIII protein of Ff phage possesses higher display valency of up to 8000 copies on its filamentous body; however, only peptides and small proteins can be displayed. The gene III protein of Ff phage with low copy number tolerates larger displays, more effectively.<xref rid="irv12697-bib-0054" ref-type="ref">54</xref>, <xref rid="irv12697-bib-0055" ref-type="ref">55</xref>, <xref rid="irv12697-bib-0056" ref-type="ref">56</xref>
</p><p>Several phages have been developed as antigen adjuvant for influenza vaccine development. A previous study incorporated influenza conserved nucleoprotein (NP) into bacteriophage P22 through genetic engineering and immunized mice were able to generate anti&#x02010;NP antibodies and CD8+ T&#x02010;cell responses specific to NP. The vaccine candidate protected mice against both H1N1 and H3N2 influenza strains that were administered via intranasal challenge.<xref rid="irv12697-bib-0057" ref-type="ref">57</xref> Two previous studies, which displayed M2e peptide on T7 and f88 phages, demonstrated that the vaccine candidate elicited protective immune responses after three subcutaneous (SC) immunizations, where a high survival rate was observed after lethal challenge with H1N1 and H2N3 virus.<xref rid="irv12697-bib-0058" ref-type="ref">58</xref>, <xref rid="irv12697-bib-0059" ref-type="ref">59</xref> Cross&#x02010;linking of M2e peptide to the T7 phage VLPs is essential in promoting this protective response, as M2e peptides that were simply mixed with T7 VLPs did not elicit protection against disease.<xref rid="irv12697-bib-0058" ref-type="ref">58</xref> Another study, which genetically fused M2e to bacteriophage Q&#x003b2; coat protein VLPs, induced a high level of M2e&#x02010;specific IgG and IgA antibodies in mice and completely protected the mice against a lethal challenge with the influenza virus PR8.<xref rid="irv12697-bib-0060" ref-type="ref">60</xref> An example of bacteriophage VLPs that have been used in human clinical trial is the gH1&#x02010;Qbeta vaccine against A/California/07/2009 (H1N1) which employs the use of RNA bacteriophage Qbeta. It was reported to induce higher antibody production compared to the same vaccine that was adjuvanted with alhydrogel, and comparable immunogenicity and safety profile to commercial vaccines.<xref rid="irv12697-bib-0061" ref-type="ref">61</xref> However, an important consideration in the design of these vaccines in the future is the possibility of developing anti&#x02010;phage antibodies in immunized individuals, hence impacting their overall balance of gut microbiota and health.<xref rid="irv12697-bib-0062" ref-type="ref">62</xref>, <xref rid="irv12697-bib-0063" ref-type="ref">63</xref>
</p></sec><sec id="irv12697-sec-0007"><label>2.1.4</label><title>Polysaccharide</title><p>Polysaccharides have various characteristics that make them suitable to be used for nanovaccine preparation, including having immunomodulatory effects and a good safety profile, as well as being biocompatible and biodegradable. They are natural polymers with glycosidically linked carbohydrate monomers.<xref rid="irv12697-bib-0064" ref-type="ref">64</xref>, <xref rid="irv12697-bib-0065" ref-type="ref">65</xref> Polysaccharides commonly comprise of chitosan and its derivatives and can function as vaccine adjuvants, given their ability to activate the immune system and promote antigen&#x02010;specific immune responses.<xref rid="irv12697-bib-0066" ref-type="ref">66</xref>, <xref rid="irv12697-bib-0067" ref-type="ref">67</xref>, <xref rid="irv12697-bib-0068" ref-type="ref">68</xref> Chitosan NPs have been previously used in influenza DNA vaccines and shown to exhibit high stability and high encapsulation rate. It was reported that the chitosan NP&#x02010;encapsulated DNA vaccine induced prolonged release of the plasmid DNA and effective immune responses are induced compared with DNA vaccine alone.<xref rid="irv12697-bib-0008" ref-type="ref">8</xref> Chitosan is approved by the US FDA for use in pharmaceuticals and food, but generally they have a few disadvantages such as poor solubility and low transfection rate that need to be considered before being used in influenza subunit vaccine development.<xref rid="irv12697-bib-0069" ref-type="ref">69</xref> Alternatively, water&#x02010;soluble trimethyl chitosan and alginate can be used as replacement for chitosan in sugar vaccine preparation. When these materials were used to package whole inactivated influenza virus and administered as vaccines, high IgG titers were elicited in immunized mice and rabbits.<xref rid="irv12697-bib-0070" ref-type="ref">70</xref>
</p></sec></sec><sec id="irv12697-sec-0008"><label>2.2</label><title>Synthetic nanoparticles</title><sec id="irv12697-sec-0009"><label>2.2.1</label><title>Biomolecular</title><sec id="irv12697-sec-0010"><title>Liposomes</title><p>Liposomes are formed through self&#x02010;assembly upon dispersion of certain amphiphilic lipids in aqueous buffer.<xref rid="irv12697-bib-0071" ref-type="ref">71</xref> These structures can be modified accordingly to achieve desirable features that suit their application purpose, such as achieving particular size and charge to enable entrapment of antigens to be used in vaccines. Liposomes can provide controlled release of antigen, while their plasticity and versatility enable them to overcome biological barriers, such as mucosa and skin. They can gain access to APCs via IM or SC injection routes and be used as both delivery vehicle and immunopotentiator.<xref rid="irv12697-bib-0072" ref-type="ref">72</xref> Advanced methods to produce liposomal vaccines, including lyophilization, cryoprotection, and sterilization, can enhance chemical stability of the lipids and widen their applicability in vaccine development.<xref rid="irv12697-bib-0073" ref-type="ref">73</xref>
</p><p>Hong and colleagues reported higher virus&#x02010;specific antibodies with long&#x02010;lasting protective immunity and 100% survival rate against lethal viral challenges for a cationic liposome&#x02010;DNA complex (CLDC)&#x02010;adjuvanted influenza vaccine candidate compared to un&#x02010;adjuvanted formulation.<xref rid="irv12697-bib-0074" ref-type="ref">74</xref>, <xref rid="irv12697-bib-0075" ref-type="ref">75</xref> A similar enhanced immunogenicity effect was reported in a study comparing between vaccination with the commercial FLUZONE&#x000ae; Quadrivalent alone and FLUZONE&#x000ae; Quadrivalent with CLDC. Only the Fluzone/CLDC&#x02010;vaccinated animals had lower virus replication when challenged with H1N1 influenza viruses.<xref rid="irv12697-bib-0076" ref-type="ref">76</xref> In another study, vaccination with liposomes containing HA and NA from various influenza strains and IL&#x02010;2/GM&#x02010;CSF as an adjuvant (INFLUSOME&#x02010;VAC) resulted in increased HAI titers compared to the control groups that received commercial influenza vaccines.<xref rid="irv12697-bib-0077" ref-type="ref">77</xref>
</p><p>Studies have shown that the dose of liposomes used in vaccines can determine the types of immune response generated. Vaxfectin, which is a commercial liposome&#x02010;based adjuvant, induced strong humoral responses in mice when used at a high dose (900&#x000a0;&#x000b5;g) with trivalent influenza vaccine (TIV), while at 30&#x000a0;&#x000b5;g of Vaxfectin, antibody responses were not induced but the amount of interferon&#x02010;&#x003b3; (IFN&#x02010;&#x003b3;) secreting T cells was increased up to 18&#x02010;fold.<xref rid="irv12697-bib-0078" ref-type="ref">78</xref> In agreement with this study, two other cationic lipid&#x02010;based adjuvants (DC&#x02010;Cholesterol and ceramide carbamoyl&#x02010;spermine) were also shown to enhance humoral responses at higher doses and cellular responses at lower doses.<xref rid="irv12697-bib-0071" ref-type="ref">71</xref>, <xref rid="irv12697-bib-0079" ref-type="ref">79</xref> This immune&#x02010;modulatory property can be explored in influenza vaccine development to produce the required immune responses just by dose modifications.</p></sec><sec id="irv12697-sec-0011"><title>Virosomes</title><p>Virosomes are lipid vesicles that incorporate virus&#x02010;derived protein and are devoid of viral genome and internal proteins.<xref rid="irv12697-bib-0080" ref-type="ref">80</xref> The membrane proteins can either be produced via recombinant technology or purified from the corresponding viruses. During surface protein purification, virus membrane is normally solubilized and reconstructed using mild detergents without causing denaturation. After solubilization, nucleocapsid and other viral components will be removed via ultracentrifugation.<xref rid="irv12697-bib-0081" ref-type="ref">81</xref>
</p><p>Virosomes are biodegradable, non&#x02010;toxic and do not induce antiphospholipid antibody responses.<xref rid="irv12697-bib-0082" ref-type="ref">82</xref> Influenza virus is most commonly used for virosome production, with each virosome averaged at approximately 150&#x000a0;nm in diameter. Almeida et al was the first to generate lipid vesicles containing NA and HA proteins derived from influenza.<xref rid="irv12697-bib-0080" ref-type="ref">80</xref> Virosomes are better adjuvants compared to liposomes because they can protect pharmaceutically active substances from proteolytic degradation at low pH within the endosomes before reaching the cytoplasm.<xref rid="irv12697-bib-0083" ref-type="ref">83</xref>, <xref rid="irv12697-bib-0084" ref-type="ref">84</xref> In addition, virosomes are good adjuvant candidates as they can specifically target APCs and effectively stimulate host B&#x02010; and T&#x02010;cell responses against attached antigens, as well as surface HA proteins.<xref rid="irv12697-bib-0085" ref-type="ref">85</xref> When used at 10&#x02010;fold lower dose, a virosome/DNA vaccine complex (consisting of NP&#x02010;encoding plasmid attached to influenza virosomes) was reported to induce comparable T&#x02010;cell responses in mice that were vaccinated with NP plasmid without virosomes.<xref rid="irv12697-bib-0086" ref-type="ref">86</xref> Inflexal&#x000ae; V, a trivalent virosome subunit vaccine suitable for use in all age&#x02010;groups, is an example of a commercially available virosome&#x02010;based influenza vaccine.<xref rid="irv12697-bib-0087" ref-type="ref">87</xref>
</p></sec><sec id="irv12697-sec-0012"><title>Immune&#x02010;stimulating complexes</title><p>Immune&#x02010;stimulating complexes (ISCOMs) are particulate adjuvant systems composed of antigen, cholesterol, phospholipid, and saponin.<xref rid="irv12697-bib-0088" ref-type="ref">88</xref> They are hollow, cage&#x02010;like particles of around 40&#x000a0;nm in diameter.<xref rid="irv12697-bib-0089" ref-type="ref">89</xref> ISCOMs combine the advantages of a particulate carrier system with the presence of an in&#x02010;built immunopotentiator (Quil A) and consequently have been found to be more immunogenic than liposomes.<xref rid="irv12697-bib-0090" ref-type="ref">90</xref> They also required substantially less antigen and other adjuvant to induce immunity in the host than vaccination with simple mixtures of free antigen and saponins.<xref rid="irv12697-bib-0091" ref-type="ref">91</xref> The use of ISCOM in vaccine formulations needs standardized procedures to produce high&#x02010;quality finished vaccines with assured batch&#x02010;to&#x02010;batch consistency. Heterogeneous mixture of ISCOM components can be separated and purified by reversed phase HPLC to eliminate potential toxic fractions in the vaccine preparation.<xref rid="irv12697-bib-0092" ref-type="ref">92</xref>, <xref rid="irv12697-bib-0093" ref-type="ref">93</xref>
</p><p>The use of ISCOM containing influenza viral proteins has been reported to enhance the CD8+ immune responses in mice and humans.<xref rid="irv12697-bib-0094" ref-type="ref">94</xref>, <xref rid="irv12697-bib-0095" ref-type="ref">95</xref> Matrix M is a third generation ISCOM and was successfully used as an adjuvant for a H7N9 VLP vaccine in a phase II clinical trial, where the adjuvanted VLP vaccine showed significantly higher seroconversion rates after vaccination compared to non&#x02010;adjuvanted VLP vaccine.<xref rid="irv12697-bib-0047" ref-type="ref">47</xref>, <xref rid="irv12697-bib-0096" ref-type="ref">96</xref> Also, in a phase I clinical trial involving 60 healthy adults, it was demonstrated that a Matrix M&#x02010;adjuvanted H5N1 (NIBRG&#x02010;14) vaccine has an acceptable safety profile, capacity for antigen dose sparing and it induced a balanced Th1/Th2 antibody and cellular responses, including multifunctional T cells.<xref rid="irv12697-bib-0097" ref-type="ref">97</xref> Furthermore, this vaccine elicited protection against highly pathogenic avian influenza A (H5N1) virus challenge in pre&#x02010;clinical murine studies.<xref rid="irv12697-bib-0098" ref-type="ref">98</xref>, <xref rid="irv12697-bib-0099" ref-type="ref">99</xref>
</p></sec></sec><sec id="irv12697-sec-0013"><label>2.2.2</label><title>Inorganic NPs</title><p>There is now increasing interest in the use of inorganic NPs as adjuvants in vaccine development. An example of inorganic NPs is gold NPs (AuNPs), which have properties that allow conjugation of target antigens or adjuvant at high densities onto their surface.<xref rid="irv12697-bib-0100" ref-type="ref">100</xref>, <xref rid="irv12697-bib-0101" ref-type="ref">101</xref> Being a natural element, synthetic AuNPs will not induce carrier&#x02010;specific immunity following immunization.<xref rid="irv12697-bib-0102" ref-type="ref">102</xref> It has been shown that a vaccine candidate made of immobilized M2e on AuNPs and soluble cytosine phosphoguanine&#x02010;oligodeoxynucleotides (CpG&#x02010;ODN) as an immunopotentiator was able to induce strong M2e&#x02010;specific antibody responses and achieve 100% survival rate in mice that were lethally challenged with influenza A/PR/8/34 (H1N1).<xref rid="irv12697-bib-0103" ref-type="ref">103</xref> The immunogenicity of these NPs can be further enhanced when used together with a bacterial component as immunopotentiator, as shown by Wang et al When both AuNP&#x02010;HA (A/Aichi/2/68(H3N2)) and TLR5 agonist flagellin (FliC)&#x02010;coupled AuNPs were co&#x02010;delivered, stronger cellular immune responses were recorded. In addition, compared with the AuNP&#x02010;HA alone group, the addition of AuNPs&#x02010;FliC improved mucosal B&#x02010;cell responses, as characterized by elevated influenza specific IgA and IgG levels in nasal, tracheal, and lung washes. AuNP&#x02010;HA/AuNP&#x02010;FliC also stimulated antigen&#x02010;specific IFN&#x02010;&#x003b3; secreting CD4+ cell proliferation.<xref rid="irv12697-bib-0104" ref-type="ref">104</xref>
</p></sec><sec id="irv12697-sec-0014"><label>2.2.3</label><title>Polymer NPs</title><p>Synthetic polymers have unique characteristics such as biocompatibility and versatility due to their chemical structure.<xref rid="irv12697-bib-0105" ref-type="ref">105</xref> They can be modified in terms of size, surface properties, and composition, which results in a controlled release and protection of drugs. PLGA (poly D,L&#x02010;lactide&#x02010;co&#x02010;glycolide) is a FDA&#x02010;approved, biodegradable synthetic polymer used for drug delivery in humans.<xref rid="irv12697-bib-0106" ref-type="ref">106</xref> They are tuneable and flexible, and their outer surface can be modified to incorporate other polymers such as chitosan for more effective mucosal vaccine delivery.<xref rid="irv12697-bib-0107" ref-type="ref">107</xref>, <xref rid="irv12697-bib-0108" ref-type="ref">108</xref> When encapsulated in PLGA NPs, antigens can be prevented from degradation for over four weeks under physiological conditions. Moreover, they can promote antigen internalization by APCs.<xref rid="irv12697-bib-0109" ref-type="ref">109</xref> PLGA NP&#x02010;based vaccines have been reported to improve the immunogenicity of several conventional and recombinant vaccines targeting human and veterinary pathogens.<xref rid="irv12697-bib-0110" ref-type="ref">110</xref>, <xref rid="irv12697-bib-0111" ref-type="ref">111</xref> Molecules that can target mucosal APCs can be covalently attached to PLGA NPs for the induction of long&#x02010;lasting and potent immune responses.<xref rid="irv12697-bib-0011" ref-type="ref">11</xref>
</p></sec></sec></sec><sec sec-type="conclusions" id="irv12697-sec-0015"><label>3</label><title>CONCLUSION</title><p>There is great potential in the use of NPs in influenza vaccine development as they can be used to deliver antigens to target cells, improve antigen stability, promote slow release of antigens, and increase immunogenicity. The availability of recombinant technology allows these nanomaterials to be further modified to achieve and boost the desired immune responses. For example, additional molecules such as TLR ligands can be added to the NPs to allow better stimulation and activation of antigen&#x02010;presenting cells. NP&#x02010;based vaccines are also safer compared to live attenuated vaccines, which pose a risk to the elderly and immunosuppressed individuals.</p><p>While there are clear advantages in using NPs as vaccine carrier and adjuvant, it is not known if results from pre&#x02010;clinical studies will translate into success in human clinical trials. To maximize the chance of success, the design of these new generation NP&#x02010;based vaccines needs to be guided by comprehensive scientific knowledge on their mechanisms of action. More studies are needed to investigate the specific ways by which different NPs interact with immune cell populations that are involved in antibody production and memory generation. The downstream immune responses such as cytokine production and complement activation should also be characterized in detail, as these responses can be protective but pathological when in excess. In addition, it should be explored if different routes of immunization can impact on the generation of long&#x02010;term immunity induced by these NP&#x02010;based vaccines. Future studies can also investigate the potential use of several types of NPs in one vaccine formulation to enhance immunogenicity. By enhancing our understanding on these issues, a safer, highly immunogenic and affordable influenza vaccine can be expected in the near future.</p></sec><sec id="irv12697-sec-0016"><title>AUTHOR CONTRIBUTIONS</title><p>AK&#x02010;H involved in writing, reviewing, and editing processes. CLL, PS, and KW involved in supervision, editing, and review process.</p></sec></body><back><ack id="irv12697-sec-0017"><title>ACKNOWLEDGEMENTS</title><p>This work was supported by Taylor's Internal Research Grant Schemes&#x02014;Major Funding Scheme (TIRGS&#x02010;MFS) No.: TRGS/MFS/2/2013/SBS/001 and Taylor's Internal Research Grant Scheme&#x02014;Emerging Research Funding Scheme (TIRGS&#x02010;ERFS) No.: TRGS/ERFS/1/2018/SBS/039 from Taylor's University, Malaysia. Atin K&#x02010;H was supported by Taylor's University Vice Chancellor Award.</p></ack><ref-list content-type="cited-references" id="irv12697-bibl-0001"><title>REFERENCES</title><ref id="irv12697-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="irv12697-cit-0001">
<collab collab-type="authors">WHO</collab>
. <article-title>Influenza fact sheet</article-title>. <year>2018</year>
<ext-link ext-link-type="uri" xlink:href="http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)">http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)</ext-link>. Accessed November 6, 2018.</mixed-citation></ref><ref id="irv12697-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="irv12697-cit-0002">
<string-name>
<surname>Subbarao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Fauci</surname>
<given-names>AS</given-names>
</string-name>. <article-title>Development of effective vaccines against pandemic influenza</article-title>. <source xml:lang="en">Immunity</source>. <year>2006</year>;<volume>24</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02010;<lpage>9</lpage>.<pub-id pub-id-type="pmid">16413916</pub-id></mixed-citation></ref><ref id="irv12697-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="irv12697-cit-0003">
<string-name>
<surname>Blyth</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Macartney</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>McRae</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel australian hospitals in 2017: results from the PAEDS&#x02010;FluCAN Collaboration</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2019</year>;<volume>68</volume>(<issue>6</issue>):<fpage>940</fpage>&#x02010;<lpage>948</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy597</pub-id>
<pub-id pub-id-type="pmid">30137244</pub-id></mixed-citation></ref><ref id="irv12697-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="irv12697-cit-0004">
<string-name>
<surname>Krammer</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Palese</surname>
<given-names>P</given-names>
</string-name>. <article-title>Influenza virus hemagglutinin stalk&#x02010;based antibodies and vaccines</article-title>. <source xml:lang="en">Curr Opin Virol</source>. <year>2013</year>;<volume>3</volume>(<issue>5</issue>):<fpage>521</fpage>&#x02010;<lpage>530</lpage>.<pub-id pub-id-type="pmid">23978327</pub-id></mixed-citation></ref><ref id="irv12697-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="irv12697-cit-0005">
<string-name>
<surname>Khurana</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Loving</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Manischewitz</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Vaccine&#x02010;induced anti&#x02010;HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease</article-title>. <source xml:lang="en">Sci Transl Med</source>. <year>2013</year>;<volume>5</volume>(<issue>200</issue>):<fpage>200ra114.</fpage>
</mixed-citation></ref><ref id="irv12697-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="irv12697-cit-0006">
<string-name>
<surname>Zhou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Trieu</surname>
<given-names>M&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Improving influenza vaccines: challenges to effective implementation</article-title>. <source xml:lang="en">Curr Opin Immunol</source>. <year>2018</year>;<volume>53</volume>:<fpage>88</fpage>&#x02010;<lpage>95</lpage>.<pub-id pub-id-type="pmid">29719276</pub-id></mixed-citation></ref><ref id="irv12697-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="irv12697-cit-0007">
<string-name>
<surname>Tregoning</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Russell</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Kinnear</surname>
<given-names>E</given-names>
</string-name>. <article-title>Adjuvanted influenza vaccines</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source>. <year>2018</year>;<volume>14</volume>(<issue>3</issue>):<fpage>550</fpage>&#x02010;<lpage>564</lpage>.<pub-id pub-id-type="pmid">29232151</pub-id></mixed-citation></ref><ref id="irv12697-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="irv12697-cit-0008">
<string-name>
<surname>Zhao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles</article-title>. <source xml:lang="en">Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>47</issue>):<fpage>8549</fpage>&#x02010;<lpage>8556</lpage>.<pub-id pub-id-type="pmid">21945253</pub-id></mixed-citation></ref><ref id="irv12697-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="irv12697-cit-0009">
<string-name>
<surname>Lalibert&#x000e9;&#x02010;Gagn&#x000e9;</surname>
<given-names>M&#x02010;&#x000c8;</given-names>
</string-name>, <string-name>
<surname>Bolduc</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Th&#x000e9;rien</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Increased immunogenicity of full&#x02010;length protein antigens through sortase&#x02010;mediated coupling on the PapMV vaccine platform</article-title>. <source xml:lang="en">Vaccines</source>. <year>2019</year>
<volume>7</volume>(<issue>2</issue>):<fpage>49</fpage>.</mixed-citation></ref><ref id="irv12697-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="irv12697-cit-0010">
<string-name>
<surname>Wusiman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Cationic polymer modified PLGA nanoparticles encapsulating <italic>Alhagi</italic> honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses</article-title>. <source xml:lang="en">Int J Nanomedicine</source>. <year>2020</year>;<volume>14</volume>:<fpage>3221</fpage>&#x02010;<lpage>3234</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="irv12697-cit-0011">
<string-name>
<surname>Ghotbi</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Haddadi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hamdy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hung</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Samuel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lavasanifar</surname>
<given-names>A</given-names>
</string-name>. <article-title>Active targeting of dendritic cells with mannan&#x02010;decorated PLGA nanoparticles</article-title>. <source xml:lang="en">J Drug Target</source>. <year>2011</year>;<volume>19</volume>(<issue>4</issue>):<fpage>281</fpage>&#x02010;<lpage>292</lpage>.<pub-id pub-id-type="pmid">20590403</pub-id></mixed-citation></ref><ref id="irv12697-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="irv12697-cit-0012">
<string-name>
<surname>Dur&#x000e1;n</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Yasar</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Preferential uptake of chitosan&#x02010;coated PLGA nanoparticles by primary human antigen presenting cells</article-title>. <source xml:lang="en">Nanomedicine</source>. <year>2019</year>;<volume>21</volume>:<fpage>102073</fpage>.<pub-id pub-id-type="pmid">31376570</pub-id></mixed-citation></ref><ref id="irv12697-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="irv12697-cit-0013">
<string-name>
<surname>Singh</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Alkie</surname>
<given-names>TN</given-names>
</string-name>, <string-name>
<surname>Nagy</surname>
<given-names>&#x000c9;</given-names>
</string-name>, <string-name>
<surname>Kulkarni</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Hodgins</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Sharif</surname>
<given-names>S</given-names>
</string-name>. <article-title>Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D, L&#x02010;lactic&#x02010;co&#x02010;glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens</article-title>. <source xml:lang="en">Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>40</issue>):<fpage>4807</fpage>&#x02010;<lpage>4813</lpage>.<pub-id pub-id-type="pmid">27543454</pub-id></mixed-citation></ref><ref id="irv12697-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="irv12697-cit-0014">
<string-name>
<surname>Cappellano</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Comi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chiocchetti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dianzani</surname>
<given-names>U</given-names>
</string-name>
<article-title>Exploiting PLGA&#x02010;based biocompatible nanoparticles for next&#x02010;generation tolerogenic vaccines against autoimmune disease</article-title>. <source xml:lang="en">Int J Mol Sci</source>. <year>2019</year>
<volume>20</volume>(<issue>1</issue>):<fpage>204</fpage>.</mixed-citation></ref><ref id="irv12697-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="irv12697-cit-0015">
<string-name>
<surname>Pati</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Shevtsov</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sonawane</surname>
<given-names>A</given-names>
</string-name>. <article-title>Nanoparticle vaccines against infectious diseases</article-title>. <source xml:lang="en">Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>2224</fpage>.<pub-id pub-id-type="pmid">30337923</pub-id></mixed-citation></ref><ref id="irv12697-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="irv12697-cit-0016">
<string-name>
<surname>Salem</surname>
<given-names>AK</given-names>
</string-name>. <article-title>Nanoparticles in vaccine delivery</article-title>. <source xml:lang="en">AAPS J</source>. <year>2015</year>;<volume>17</volume>(<issue>2</issue>):<fpage>289</fpage>&#x02010;<lpage>291</lpage>.<pub-id pub-id-type="pmid">25613459</pub-id></mixed-citation></ref><ref id="irv12697-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="irv12697-cit-0017">
<collab collab-type="authors">FDA</collab>
. <article-title>Considering whether an FDAregulated product involves the application of Nanotechnology</article-title>. <year>2011</year>.</mixed-citation></ref><ref id="irv12697-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="irv12697-cit-0018">
<string-name>
<surname>Zhao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Seth</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wibowo</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Nanoparticle vaccines</article-title>. <source xml:lang="en">Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>3</issue>):<fpage>327</fpage>&#x02010;<lpage>337</lpage>.<pub-id pub-id-type="pmid">24295808</pub-id></mixed-citation></ref><ref id="irv12697-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="irv12697-cit-0019">
<string-name>
<surname>Pulendran</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>R</given-names>
</string-name>. <article-title>Immunological mechanisms of vaccination</article-title>. <source xml:lang="en">Nat Immunol</source>. <year>2011</year>;<volume>12</volume>(<issue>6</issue>):<fpage>509</fpage>&#x02010;<lpage>517</lpage>.<pub-id pub-id-type="pmid">21739679</pub-id></mixed-citation></ref><ref id="irv12697-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="irv12697-cit-0020">
<string-name>
<surname>Thakur</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Jungersen</surname>
<given-names>G</given-names>
</string-name>. <article-title>Immune markers and correlates of protection for vaccine induced immune responses</article-title>. <source xml:lang="en">Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>33</issue>):<fpage>4907</fpage>&#x02010;<lpage>4920</lpage>.<pub-id pub-id-type="pmid">22658928</pub-id></mixed-citation></ref><ref id="irv12697-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="irv12697-cit-0021">
<string-name>
<surname>Fritze</surname>
<given-names>D</given-names>
</string-name>. <article-title>Taxonomy of the Genus <italic>Bacillus</italic> and Related Genera: the aerobic endospore&#x02010;forming bacteria</article-title>. <source xml:lang="en">Phytopathology</source>. <year>2004</year>;<volume>94</volume>(<issue>11</issue>):<fpage>1245</fpage>&#x02010;<lpage>1248</lpage>.<pub-id pub-id-type="pmid">18944461</pub-id></mixed-citation></ref><ref id="irv12697-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="irv12697-cit-0022">
<string-name>
<surname>McKenney</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Driks</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Eichenberger</surname>
<given-names>P</given-names>
</string-name>. <article-title>The <italic>Bacillus subtilis</italic> endospore: assembly and functions of the multilayered coat</article-title>. <source xml:lang="en">Nat Rev Microbiol</source>. <year>2012</year>;<volume>11</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">23202530</pub-id></mixed-citation></ref><ref id="irv12697-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="irv12697-cit-0023">
<string-name>
<surname>Chen</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Mahadevan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Driks</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sahin</surname>
<given-names>O</given-names>
</string-name>
<article-title>
<italic>Bacillus</italic> spores as building blocks for stimuli&#x02010;responsive materials and nanogenerators</article-title>. <source xml:lang="en">Nat Nanotechnol</source>. <year>2014</year>;<volume>9</volume>:<fpage>137</fpage>.<pub-id pub-id-type="pmid">24463362</pub-id></mixed-citation></ref><ref id="irv12697-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="irv12697-cit-0024">
<string-name>
<surname>Zhao</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Miao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Development of a heat&#x02010;stable and orally delivered recombinant M2e&#x02010;expressing <italic>B subtilis</italic> spore&#x02010;based influenza vaccine</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source>. <year>2014</year>;<volume>10</volume>(<issue>12</issue>):<fpage>3649</fpage>&#x02010;<lpage>3658</lpage>.<pub-id pub-id-type="pmid">25483702</pub-id></mixed-citation></ref><ref id="irv12697-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="irv12697-cit-0025">
<string-name>
<surname>Ferreira</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schumann</surname>
<given-names>W</given-names>
</string-name>. <article-title>
<italic>Bacillus subtilis</italic>as a tool for vaccine development: from antigen factories to delivery vectors</article-title>. <source xml:lang="en">An Acad Bras Cienc</source>. <year>2005</year>;<volume>77</volume>:<fpage>113&#x02013;124.</fpage>
<ext-link ext-link-type="uri" xlink:href="http://www.scielo.br/scielo.php?script=sci_arttext&#x00026;pxml:id=S0001-37652005000100009&#x00026;nrm=iso">http://www.scielo.br/scielo.php?script=sci_arttext&#x00026;pxml:id=S0001-37652005000100009&#x00026;nrm=iso</ext-link>
<pub-id pub-id-type="pmid">15692682</pub-id></mixed-citation></ref><ref id="irv12697-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="irv12697-cit-0026">
<string-name>
<surname>Ciabattini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Parigi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Isticato</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Oggioni</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Pozzi</surname>
<given-names>G</given-names>
</string-name>. <article-title>Oral priming of mice by recombinant spores of <italic>Bacillus subtilis</italic>
</article-title>. <source xml:lang="en">Vaccine</source>. <year>2004</year>;<volume>22</volume>(<issue>31</issue>):<fpage>4139</fpage>&#x02010;<lpage>4143</lpage>.<pub-id pub-id-type="pmid">15474704</pub-id></mixed-citation></ref><ref id="irv12697-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="irv12697-cit-0027">
<string-name>
<surname>Duc</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Fairweather</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ricca</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cutting</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Bacterial spores as vaccine vehicles</article-title>. <source xml:lang="en">Infect Immun</source>. <year>2003</year>;<volume>71</volume>(<issue>5</issue>):<fpage>2810</fpage>&#x02010;<lpage>2818</lpage>.<pub-id pub-id-type="pmid">12704155</pub-id></mixed-citation></ref><ref id="irv12697-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="irv12697-cit-0028">
<string-name>
<surname>de Souza</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Batista</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Luiz</surname>
<given-names>WB</given-names>
</string-name>, et al. <article-title>
<italic>Bacillus subtilis</italic> Spores as Vaccine Adjuvants: Further Insights into the Mechanisms of Action</article-title>. <source xml:lang="en">PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>1</issue>):<elocation-id>e87454</elocation-id>.<pub-id pub-id-type="pmid">24475289</pub-id></mixed-citation></ref><ref id="irv12697-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="irv12697-cit-0029">
<string-name>
<surname>Ricca</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Baccigalupi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cangiano</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>De Felice</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Isticato</surname>
<given-names>R</given-names>
</string-name>. <article-title>Mucosal vaccine delivery by non&#x02010;recombinant spores of <italic>Bacillus subtilis</italic>
</article-title>. <source xml:lang="en">Microb Cell Fact</source>. <year>2014</year>;<volume>13</volume>(<issue>1</issue>):<fpage>115</fpage>.<pub-id pub-id-type="pmid">25112405</pub-id></mixed-citation></ref><ref id="irv12697-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="irv12697-cit-0030">
<string-name>
<surname>&#x00141;&#x00119;ga</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Weiher</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Obuchowski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nidzworski</surname>
<given-names>D</given-names>
</string-name>. <article-title>Presenting Influenza A M2e antigen on recombinant spores of <italic>Bacillus subtilis</italic>
</article-title>. <source xml:lang="en">PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>11</issue>):<elocation-id>e0167225</elocation-id>.<pub-id pub-id-type="pmid">27902762</pub-id></mixed-citation></ref><ref id="irv12697-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="irv12697-cit-0031">
<string-name>
<surname>Song</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>J&#x02010;M</given-names>
</string-name>, et al. <article-title>Killed <italic>Bacillus subtilis</italic> spores as a mucosal adjuvant for an H5N1 vaccine</article-title>. <source xml:lang="en">Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>22</issue>):<fpage>3266</fpage>&#x02010;<lpage>3277</lpage>.<pub-id pub-id-type="pmid">22446640</pub-id></mixed-citation></ref><ref id="irv12697-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="irv12697-cit-0032">
<string-name>
<surname>Grgacic</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Virus&#x02010;like particles: passport to immune recognition</article-title>. <source xml:lang="en">Methods</source>. <year>2006</year>;<volume>40</volume>(<issue>1</issue>):<fpage>60</fpage>&#x02010;<lpage>65</lpage>.<pub-id pub-id-type="pmid">16997714</pub-id></mixed-citation></ref><ref id="irv12697-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="irv12697-cit-0033">
<string-name>
<surname>Young</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>T</given-names>
</string-name>. <article-title>Particle&#x02010;based vaccines for HIV&#x02010;1 infection</article-title>. <source xml:lang="en">Curr Drug Targets&#x02010;Infectious Disord</source>. <year>2003</year>;<volume>3</volume>(<issue>2</issue>):<fpage>151</fpage>&#x02010;<lpage>169</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="irv12697-cit-0034">
<string-name>
<surname>Wang</surname>
<given-names>B&#x02010;Z</given-names>
</string-name>, <string-name>
<surname>Quan</surname>
<given-names>F&#x02010;S</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>S&#x02010;M</given-names>
</string-name>, <string-name>
<surname>Bozja</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Skountzou</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Compans</surname>
<given-names>RW</given-names>
</string-name>. <article-title>Incorporation of Membrane&#x02010;Anchored Flagellin into Influenza Virus&#x02010;Like Particles Enhances the Breadth of Immune Responses</article-title>. <source xml:lang="en">J Virol</source>. <year>2008</year>;<volume>82</volume>(<issue>23</issue>):<fpage>11813</fpage>&#x02010;<lpage>11823</lpage>.<pub-id pub-id-type="pmid">18786995</pub-id></mixed-citation></ref><ref id="irv12697-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="irv12697-cit-0035">
<string-name>
<surname>Kovacsovics&#x02010;Bankowski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Benacerraf</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rock</surname>
<given-names>K</given-names>
</string-name>. <article-title>Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>1993</year>;<volume>11</volume>(<issue>90</issue>):<fpage>4942</fpage>&#x02010;<lpage>4946</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="irv12697-cit-0036">
<string-name>
<surname>Harding</surname>
<given-names>CV</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>R</given-names>
</string-name>. <article-title>Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules</article-title>. <source xml:lang="en">Immunol</source>. <year>1994</year>;<volume>11</volume>(<issue>153</issue>):<fpage>4925</fpage>&#x02010;<lpage>4933</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="irv12697-cit-0037">
<string-name>
<surname>Zhao</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Modis</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Virus&#x02010;like particle&#x02010;based human vaccines: quality assessment based on structural and functional properties</article-title>. <source xml:lang="en">Trends Biotechnol</source>. <year>2013</year>;<volume>31</volume>(<issue>11</issue>):<fpage>654</fpage>&#x02010;<lpage>663</lpage>.<pub-id pub-id-type="pmid">24125746</pub-id></mixed-citation></ref><ref id="irv12697-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="irv12697-cit-0038">
<string-name>
<surname>Ren</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Intramuscular and intranasal immunization with an H7N9 influenza virus&#x02010;like particle vaccine protects mice against lethal influenza virus challenge</article-title>. <source xml:lang="en">Int Immunopharmacol</source>. <year>2017</year>;<volume>2018</volume>(<issue>58</issue>):<fpage>109</fpage>&#x02010;<lpage>116</lpage>.s</mixed-citation></ref><ref id="irv12697-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="irv12697-cit-0039">
<string-name>
<surname>Bright</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Daniluk</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Influenza virus&#x02010;like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin</article-title>. <source xml:lang="en">Vaccine</source>. <year>2007</year>;<volume>25</volume>(<issue>19</issue>):<fpage>3871</fpage>&#x02010;<lpage>3878</lpage>.<pub-id pub-id-type="pmid">17337102</pub-id></mixed-citation></ref><ref id="irv12697-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="irv12697-cit-0040">
<string-name>
<surname>Kim</surname>
<given-names>M&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>J&#x02010;M</given-names>
</string-name>, <string-name>
<surname>Eunju</surname>
<given-names>O</given-names>
</string-name>, et al. <article-title>Virus&#x02010;like particles containing multiple M2 extracellular domains confer improved cross&#x02010;protection against various subtypes of Influenza virus</article-title>. <source xml:lang="en">Mol Ther</source>. <year>2013</year>;<volume>21</volume>(<issue>2</issue>):<fpage>485</fpage>&#x02010;<lpage>492</lpage>.<pub-id pub-id-type="pmid">23247101</pub-id></mixed-citation></ref><ref id="irv12697-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="irv12697-cit-0041">
<string-name>
<surname>Kim</surname>
<given-names>M&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>Y&#x02010;N</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>HS</given-names>
</string-name>, et al. <article-title>Influenza M2 virus&#x02010;like particles confer a broader range of cross protection to the strain&#x02010;specific pre&#x02010;existing immunity</article-title>. <source xml:lang="en">Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>44</issue>):<fpage>5824</fpage>&#x02010;<lpage>5831</lpage>.<pub-id pub-id-type="pmid">25171841</pub-id></mixed-citation></ref><ref id="irv12697-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="irv12697-cit-0042">
<string-name>
<surname>Music</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Reber</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>M&#x02010;C</given-names>
</string-name>, <string-name>
<surname>York</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>S&#x02010;M</given-names>
</string-name>. <article-title>Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus&#x02010;like particles confers improved cross&#x02010;protection in ferrets</article-title>. <source xml:lang="en">Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>4</issue>):<fpage>466</fpage>&#x02010;<lpage>473</lpage>.<pub-id pub-id-type="pmid">26709639</pub-id></mixed-citation></ref><ref id="irv12697-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="irv12697-cit-0043">
<string-name>
<surname>Ramirez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Maucourant</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A virus&#x02010;like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles</article-title>. <source xml:lang="en">Vaccine</source>. <year>2018</year>;<volume>36</volume>:<fpage>873</fpage>&#x02010;<lpage>880</lpage>.<pub-id pub-id-type="pmid">29306508</pub-id></mixed-citation></ref><ref id="irv12697-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="irv12697-cit-0044">
<string-name>
<surname>Gao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Enhanced Influenza VLP vaccines comprising matrix&#x02010;2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2013</year>;<volume>98</volume>(<issue>1</issue>):<fpage>4</fpage>&#x02010;<lpage>11</lpage>.<pub-id pub-id-type="pmid">23416215</pub-id></mixed-citation></ref><ref id="irv12697-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="irv12697-cit-0045">
<string-name>
<surname>Schwartzman</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Cathcart</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Pujanauski</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Qi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kash</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Taubenberger</surname>
<given-names>JK</given-names>
</string-name>. <article-title>An intranasal virus&#x02010;like particle vaccine broadly protects mice from multiple subtypes of influenza a virus</article-title>. <source xml:lang="en">MBio</source>. <year>2015</year>;<volume>6</volume>(<issue>4</issue>):<fpage>1</fpage>&#x02010;<lpage>9</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="irv12697-cit-0046">
<string-name>
<surname>L&#x000f3;pez&#x02010;Mac&#x000ed;as</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ferat&#x02010;Osorio</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tenorio&#x02010;Calvo</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Safety and immunogenicity of a virus&#x02010;like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo&#x02010;controlled trial of adults in Mexico</article-title>. <source xml:lang="en">Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>44</issue>):<fpage>7826</fpage>&#x02010;<lpage>7834</lpage>.<pub-id pub-id-type="pmid">21816199</pub-id></mixed-citation></ref><ref id="irv12697-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="irv12697-cit-0047">
<string-name>
<surname>Fries</surname>
<given-names>LF</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Glenn</surname>
<given-names>GM</given-names>
</string-name>. <article-title>A recombinant viruslike particle Influenza A (H7N9) vaccine</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2013</year>;<volume>369</volume>(<issue>26</issue>):<fpage>2564</fpage>&#x02010;<lpage>2566</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="irv12697-cit-0048">
<string-name>
<surname>Taylor</surname>
<given-names>DN</given-names>
</string-name>, <string-name>
<surname>Treanor</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Strout</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Induction of a potent immune response in the elderly using the TLR&#x02010;5 agonist, flagellin, with a recombinant hemagglutinin influenza&#x02013;flagellin fusion vaccine (VAX125, STF2.HA1 SI)</article-title>. <source xml:lang="en">Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>31</issue>):<fpage>4897</fpage>&#x02010;<lpage>4902</lpage>.<pub-id pub-id-type="pmid">21596084</pub-id></mixed-citation></ref><ref id="irv12697-bib-0049"><label>49</label><mixed-citation publication-type="miscellaneous" id="irv12697-cit-0049">
<article-title>Novavax Announces Positive Phase 2 NanoFlu results in older adults</article-title>. <ext-link ext-link-type="uri" xlink:href="https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-phase-2-nanofluresults-older-adults">https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-phase-2-nanofluresults-older-adults</ext-link>
</mixed-citation></ref><ref id="irv12697-bib-0050"><label>50</label><mixed-citation publication-type="miscellaneous" id="irv12697-cit-0050">
<article-title>Efficacy of a plant&#x02010;derived QUADRIVALENT VLP vaccine in the elderly</article-title>. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03739112">https://clinicaltrials.gov/ct2/show/NCT03739112</ext-link>
</mixed-citation></ref><ref id="irv12697-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="irv12697-cit-0051">
<string-name>
<surname>Turley</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Rupp</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Safety and immunogenicity of a recombinant M2e&#x02013;flagellin influenza vaccine (STF2.4xM2e) in healthy adults</article-title>. <source xml:lang="en">Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>32</issue>):<fpage>5145</fpage>&#x02010;<lpage>5152</lpage>.<pub-id pub-id-type="pmid">21624416</pub-id></mixed-citation></ref><ref id="irv12697-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="irv12697-cit-0052">
<string-name>
<surname>Tao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mahalingam</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Batra</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>VB</given-names>
</string-name>. <article-title>Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases</article-title>. <source xml:lang="en">Adv Drug Deliv Rev</source>. <year>2018</year> pii: S0169-409X(18)30164-9. <pub-id pub-id-type="doi">10.1016/j.addr.2018.06.025</pub-id>. [Epub ahead of print].</mixed-citation></ref><ref id="irv12697-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="irv12697-cit-0053">
<string-name>
<surname>Barfoot</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Denham</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gyure</surname>
<given-names>LA</given-names>
</string-name>, et al. <article-title>Some properties of dendritic macrophages from peripheral lymph</article-title>. <source xml:lang="en">Immunology</source>. <year>1989</year>;<volume>68</volume>(<issue>2</issue>):<fpage>233</fpage>&#x02010;<lpage>239</lpage>.<pub-id pub-id-type="pmid">2807381</pub-id></mixed-citation></ref><ref id="irv12697-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="irv12697-cit-0054">
<string-name>
<surname>Huang</surname>
<given-names>JX</given-names>
</string-name>, <string-name>
<surname>Bishop&#x02010;Hurley</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Development of anti&#x02010;infectives using phage display: biological agents against bacteria, viruses, and parasites</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2012</year>;<volume>56</volume>(<issue>9</issue>):<fpage>4569</fpage>&#x02010;<lpage>4582</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00567-12</pub-id>
<pub-id pub-id-type="pmid">22664969</pub-id></mixed-citation></ref><ref id="irv12697-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="irv12697-cit-0055">
<string-name>
<surname>Deng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>You</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Dai</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Advances in the T7 phage display system (Review)</article-title>. <source xml:lang="en">Mol Med Rep</source>. <year>2018</year>;<volume>17</volume>(<issue>1</issue>):<fpage>714</fpage>&#x02010;<lpage>720</lpage>.<pub-id pub-id-type="pmid">29115536</pub-id></mixed-citation></ref><ref id="irv12697-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="irv12697-cit-0056">
<string-name>
<surname>Ledsgaard</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kilstrup</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Karatt&#x02010;Vellatt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McCafferty</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Laustsen</surname>
<given-names>HA</given-names>
</string-name>. <article-title>Basics of antibody phage display</article-title>. <source xml:lang="en">Technology. Toxins</source>. <year>2018</year>
<volume>10</volume>(<issue>6</issue>):<fpage>236</fpage>.</mixed-citation></ref><ref id="irv12697-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="irv12697-cit-0057">
<string-name>
<surname>Patterson</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Rynda&#x02010;Apple</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Harmsen</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Harmsen</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Douglas</surname>
<given-names>T</given-names>
</string-name>. <article-title>Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza</article-title>. <source xml:lang="en">ACS Nano</source>. <year>2013</year>;<volume>7</volume>(<issue>4</issue>):<fpage>3036</fpage>&#x02010;<lpage>3044</lpage>.<pub-id pub-id-type="pmid">23540530</pub-id></mixed-citation></ref><ref id="irv12697-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="irv12697-cit-0058">
<string-name>
<surname>Hashemi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pouyanfard</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bandehpour</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Immunization with M2e&#x02010;Displaying T7 bacteriophage nanoparticles protects against Influenza A virus challenge</article-title>. <source xml:lang="en">PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>9</issue>):<elocation-id>e45765</elocation-id>.<pub-id pub-id-type="pmid">23029232</pub-id></mixed-citation></ref><ref id="irv12697-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="irv12697-cit-0059">
<string-name>
<surname>Deng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Iba&#x000f1;ez</surname>
<given-names>LI</given-names>
</string-name>, <string-name>
<surname>Van Den Bossche</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Protection against influenza a virus challenge with M2e&#x02010;displaying filamentous Escherichia coli phages</article-title>. <source xml:lang="en">PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>5</issue>):<elocation-id>e0126650</elocation-id>.<pub-id pub-id-type="pmid">25973787</pub-id></mixed-citation></ref><ref id="irv12697-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="irv12697-cit-0060">
<string-name>
<surname>Bessa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schmitz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hinton</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Schwarz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jegerlehner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bachmann</surname>
<given-names>MF</given-names>
</string-name>. <article-title>Efficient induction of mucosal and systemic immune responses by virus&#x02010;like particles administered intranasally: implications for vaccine design</article-title>. <source xml:lang="en">Eur J Immunol</source>. <year>2007</year>;<volume>38</volume>(<issue>1</issue>):<fpage>114</fpage>&#x02010;<lpage>126</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="irv12697-cit-0061">
<string-name>
<surname>Low</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Ooi</surname>
<given-names>EE</given-names>
</string-name>, et al. <article-title>Safety and immunogenicity of a virus&#x02010;like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double&#x02010;blinded, randomized Phase I clinical trial in healthy Asian volunteers</article-title>. <source xml:lang="en">Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>39</issue>):<fpage>5041</fpage>&#x02010;<lpage>5048</lpage>.<pub-id pub-id-type="pmid">25045806</pub-id></mixed-citation></ref><ref id="irv12697-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="irv12697-cit-0062">
<string-name>
<surname>Van Belleghem</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>D&#x00105;browska</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Vaneechoutte</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barr</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Bollyky</surname>
<given-names>LP</given-names>
</string-name>. <article-title>Interactions between bacteriophage, bacteria, and the mammalian immune system</article-title>. <source xml:lang="en">Viruses</source>. <year>2018</year>;<volume>11</volume>(<issue>1</issue>):<fpage>10</fpage>.</mixed-citation></ref><ref id="irv12697-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="irv12697-cit-0063">
<string-name>
<surname>Ciabattini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Olivieri</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lazzeri</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Medaglini</surname>
<given-names>D</given-names>
</string-name>. <article-title>Role of the microbiota in the modulation of vaccine immune responses</article-title>. <source xml:lang="en">Front Microbiol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1305</fpage>.<pub-id pub-id-type="pmid">31333592</pub-id></mixed-citation></ref><ref id="irv12697-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="irv12697-cit-0064">
<string-name>
<surname>Ferreira</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Passos</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Madureira</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vilanova</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Coimbra</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Structure&#x02010;function relationships of immunostimulatory polysaccharides: A review</article-title>. <source xml:lang="en">Carbohydr Polym</source>. <year>2015</year>;<volume>132</volume>:<fpage>378</fpage>&#x02010;<lpage>396</lpage>.<pub-id pub-id-type="pmid">26256362</pub-id></mixed-citation></ref><ref id="irv12697-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="irv12697-cit-0065">
<string-name>
<surname>Sun</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>K</given-names>
</string-name>. <article-title>Polysaccharides as vaccine adjuvants</article-title>. <source xml:lang="en">Vaccine</source>. <year>2018</year>;<volume>36</volume>(<issue>35</issue>):<fpage>5226</fpage>&#x02010;<lpage>5234</lpage>.<pub-id pub-id-type="pmid">30057282</pub-id></mixed-citation></ref><ref id="irv12697-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="irv12697-cit-0066">
<string-name>
<surname>Luo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>X</given-names>
</string-name>. <article-title>Research overview of Chinese medicine as vaccine adjuvant</article-title>. <source xml:lang="en">Chinese J Vet Med</source>. <year>2009</year>;<volume>45</volume>:<fpage>61</fpage>&#x02010;<lpage>63</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="irv12697-cit-0067">
<string-name>
<surname>Wei</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Dan</surname>
<given-names>J</given-names>
</string-name>. <article-title>Application of polysaccharide adjuvant in vaccine</article-title>. <source xml:lang="en">Chinese J New Drugs</source>. <year>2012</year>;<volume>21</volume>:<fpage>1470</fpage>&#x02010;<lpage>1478</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="irv12697-cit-0068">
<string-name>
<surname>Mbow</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>De Gregorio</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Valiante</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Rappuoli</surname>
<given-names>R</given-names>
</string-name>. <article-title>New adjuvants for human vaccines</article-title>. <source xml:lang="en">Curr Opin Immunol</source>. <year>2010</year>;<volume>22</volume>(<issue>3</issue>):<fpage>411</fpage>&#x02010;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2010.04.004</pub-id>.<pub-id pub-id-type="pmid">20466528</pub-id></mixed-citation></ref><ref id="irv12697-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="irv12697-cit-0069">
<string-name>
<surname>Singla</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Chawla</surname>
<given-names>M</given-names>
</string-name>. <article-title>Chitosan: some pharmaceutical and biological aspects &#x02010; an update</article-title>. <source xml:lang="en">J Pharm Pharmacol</source>. <year>2001</year>;<volume>53</volume>(<issue>8</issue>):<fpage>1047</fpage>&#x02010;<lpage>1067</lpage>.<pub-id pub-id-type="pmid">11518015</pub-id></mixed-citation></ref><ref id="irv12697-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="irv12697-cit-0070">
<string-name>
<surname>Mosafer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sabbaghi</surname>
<given-names>A&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Badiee</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dehghan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tafaghodi</surname>
<given-names>M</given-names>
</string-name>. <article-title>Preparation, characterization and in vivo evaluation of alginate&#x02010;coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization</article-title>. <source xml:lang="en">Asian J Pharm Sci</source>. <year>2020</year>;<volume>14</volume>(<issue>2</issue>):<fpage>216</fpage>&#x02010;<lpage>221</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="irv12697-cit-0071">
<string-name>
<surname>Bangham</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Lipid Bilayers and Biomembranes</article-title>. <source xml:lang="en">Annu Rev Biochem</source>. <year>1972</year>;<volume>41</volume>(<issue>1</issue>):<fpage>753</fpage>&#x02010;<lpage>776</lpage>.<pub-id pub-id-type="pmid">4563442</pub-id></mixed-citation></ref><ref id="irv12697-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="irv12697-cit-0072">
<string-name>
<surname>Schwendener</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Liposomes as vaccine delivery systems: a review of the recent advances</article-title>. <source xml:lang="en">Ther Adv Vaccines</source>. <year>2014</year>;<volume>2</volume>(<issue>6</issue>):<fpage>159</fpage>&#x02010;<lpage>182</lpage>.<pub-id pub-id-type="pmid">25364509</pub-id></mixed-citation></ref><ref id="irv12697-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="irv12697-cit-0073">
<string-name>
<surname>Mohammed</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Bramwell</surname>
<given-names>VW</given-names>
</string-name>, <string-name>
<surname>Coombes</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Perrie</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products</article-title>. <source xml:lang="en">Methods</source>. <year>2006</year>;<volume>40</volume>(<issue>1</issue>):<fpage>30</fpage>&#x02010;<lpage>38</lpage>.<pub-id pub-id-type="pmid">16997711</pub-id></mixed-citation></ref><ref id="irv12697-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="irv12697-cit-0074">
<string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fairman</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Cationic liposome&#x02013;DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross&#x02010;protective efficacy of a pre&#x02010;pandemic influenza A H5N1 vaccine in mice</article-title>. <source xml:lang="en">Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>2</issue>):<fpage>254</fpage>&#x02010;<lpage>264</lpage>.<pub-id pub-id-type="pmid">22085545</pub-id></mixed-citation></ref><ref id="irv12697-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="irv12697-cit-0075">
<string-name>
<surname>Hong</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Botham</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Giffon</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Fairman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>DB</given-names>
</string-name>. <article-title>Cationic lipid/DNA complex&#x02010;adjuvanted influenza a virus vaccination induces robust cross&#x02010;protective immunity</article-title>. <source xml:lang="en">J Virol</source>. <year>2010</year>;<volume>84</volume>(<issue>24</issue>):<fpage>12691</fpage>&#x02010;<lpage>12702</lpage>. <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/84/24/12691.abstract">http://jvi.asm.org/content/84/24/12691.abstract</ext-link>.<pub-id pub-id-type="pmid">20943978</pub-id></mixed-citation></ref><ref id="irv12697-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="irv12697-cit-0076">
<string-name>
<surname>Lay</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Callejo</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Cationic lipid/DNA complexes (JVRS&#x02010;100) combined with influenza vaccine (Fluzone&#x000ae;) increases antibody response, cellular immunity, and antigenically drifted protection</article-title>. <source xml:lang="en">Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>29</issue>):<fpage>3811</fpage>&#x02010;<lpage>3820</lpage>.<pub-id pub-id-type="pmid">19406188</pub-id></mixed-citation></ref><ref id="irv12697-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="irv12697-cit-0077">
<string-name>
<surname>Ben&#x02010;Yehuda</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Joseph</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zeira</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME&#x02010;VAC) in young adults</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2003</year>;<volume>69</volume>(<issue>4</issue>):<fpage>560</fpage>&#x02010;<lpage>567</lpage>.<pub-id pub-id-type="pmid">12601765</pub-id></mixed-citation></ref><ref id="irv12697-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="irv12697-cit-0078">
<string-name>
<surname>Hartikka</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bozoukova</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>CK</given-names>
</string-name>, et al. <article-title>Vaxfectin&#x000ae;, a cationic lipid&#x02010;based adjuvant for protein&#x02010;based influenza vaccines</article-title>. <source xml:lang="en">Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>46</issue>):<fpage>6399</fpage>&#x02010;<lpage>6403</lpage>.<pub-id pub-id-type="pmid">19552895</pub-id></mixed-citation></ref><ref id="irv12697-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="irv12697-cit-0079">
<string-name>
<surname>Lasic</surname>
<given-names>DD</given-names>
</string-name>. <article-title>Novel applications of liposomes</article-title>. <source xml:lang="en">Trends Biotechnol</source>. <year>1998</year>;<volume>16</volume>(<issue>7</issue>):<fpage>307</fpage>&#x02010;<lpage>321</lpage>.<pub-id pub-id-type="pmid">9675915</pub-id></mixed-citation></ref><ref id="irv12697-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="irv12697-cit-0080">
<string-name>
<surname>Almeida</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Brand</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Heath</surname>
<given-names>T</given-names>
</string-name>. <article-title>Formation of virosomes from influenza subunits and liposomes</article-title>. <source xml:lang="en">Lancet</source>. <year>1975</year>;<volume>306</volume>(<issue>7941</issue>):<fpage>899</fpage>&#x02010;<lpage>901</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="irv12697-cit-0081">
<string-name>
<surname>Stegmann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Morselt</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Booy</surname>
<given-names>FP</given-names>
</string-name>, <string-name>
<surname>Breemen</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Scherphof</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wilschut</surname>
<given-names>J</given-names>
</string-name>. <article-title>Functional reconstitution of influenza virus envelopes</article-title>. <source xml:lang="en">EMBO J</source>. <year>1987</year>;<volume>6</volume>(<issue>9</issue>):<fpage>2651</fpage>&#x02010;<lpage>2659</lpage>.<pub-id pub-id-type="pmid">3678202</pub-id></mixed-citation></ref><ref id="irv12697-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="irv12697-cit-0082">
<string-name>
<surname>Cryz</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Que</surname>
<given-names>JU</given-names>
</string-name>, <string-name>
<surname>Gl&#x000fc;ck</surname>
<given-names>R</given-names>
</string-name>. <article-title>A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans</article-title>. <source xml:lang="en">Vaccine</source>. <year>1996</year>;<volume>14</volume>(<issue>14</issue>):<fpage>1381</fpage>&#x02010;<lpage>1383</lpage>.<pub-id pub-id-type="pmid">9004449</pub-id></mixed-citation></ref><ref id="irv12697-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="irv12697-cit-0083">
<string-name>
<surname>Kaneda</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Virosomes: evolution of the liposome as a targeted drug delivery system</article-title>. <source xml:lang="en">Adv Drug Deliv Rev</source>. <year>2000</year>;<volume>43</volume>(<issue>2</issue>):<fpage>197</fpage>&#x02010;<lpage>205</lpage>.<pub-id pub-id-type="pmid">10967226</pub-id></mixed-citation></ref><ref id="irv12697-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="irv12697-cit-0084">
<string-name>
<surname>Huckriede</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bungener</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Stegmann</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>The virosome concept for influenza vaccines</article-title>. <source xml:lang="en">Vaccine</source>. <year>2005</year>;<volume>23</volume>:<fpage>S26</fpage>&#x02010;<lpage>S38</lpage>.<pub-id pub-id-type="pmid">16026906</pub-id></mixed-citation></ref><ref id="irv12697-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="irv12697-cit-0085">
<string-name>
<surname>Moser</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Amacker</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kammer</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Rasi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Westerfeld</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zurbriggen</surname>
<given-names>R</given-names>
</string-name>. <article-title>Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations</article-title>. <source xml:lang="en">Expert Rev Vaccines</source>. <year>2007</year>;<volume>6</volume>(<issue>5</issue>):<fpage>711</fpage>&#x02010;<lpage>721</lpage>.<pub-id pub-id-type="pmid">17931152</pub-id></mixed-citation></ref><ref id="irv12697-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="irv12697-cit-0086">
<string-name>
<surname>Kheiri</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Jamali</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shenagari</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Influenza virosome/DNA vaccine complex as a new formulation to induce intra&#x02010;subtypic protection against influenza virus challenge</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2012</year>;<volume>95</volume>(<issue>3</issue>):<fpage>229</fpage>&#x02010;<lpage>236</lpage>.<pub-id pub-id-type="pmid">22809863</pub-id></mixed-citation></ref><ref id="irv12697-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="irv12697-cit-0087">
<string-name>
<surname>Mischler</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Metcalfe</surname>
<given-names>IC</given-names>
</string-name>. <article-title>Inflexal&#x000ae;V a trivalent virosome subunit influenza vaccine: production</article-title>. <source xml:lang="en">Vaccine</source>. <year>2002</year>;<volume>20</volume>:<fpage>B17</fpage>&#x02010;<lpage>B23</lpage>.<pub-id pub-id-type="pmid">12477413</pub-id></mixed-citation></ref><ref id="irv12697-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="irv12697-cit-0088">
<string-name>
<surname>Lovgren</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Morein</surname>
<given-names>B</given-names>
</string-name>. <article-title>The requirement of lipids for the formation of immunostimulating complexes (iscoms)</article-title>. <source xml:lang="en">Biotechnol Appl Biochem</source>. <year>1988</year>;<volume>10</volume>(<issue>2</issue>):<fpage>161</fpage>&#x02010;<lpage>172</lpage>.<pub-id pub-id-type="pmid">2838046</pub-id></mixed-citation></ref><ref id="irv12697-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="irv12697-cit-0089">
<string-name>
<surname>Kersten</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Spiekstra</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Coen Beuvery</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Crommelin</surname>
<given-names>D</given-names>
</string-name>. <article-title>On the structure of immune&#x02010;stimulating saponin&#x02010;lipid complexes (iscoms)</article-title>. <source xml:lang="en">Biochim Biophys Acta</source>. <year>1991</year>;<volume>1062</volume>(<issue>2</issue>):<fpage>165</fpage>&#x02010;<lpage>171</lpage>.<pub-id pub-id-type="pmid">2004105</pub-id></mixed-citation></ref><ref id="irv12697-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="irv12697-cit-0090">
<string-name>
<surname>Sanders</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Deliyannis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pearse</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>ISCOM<sup>TM</sup>&#x02010;based vaccines: The second decade</article-title>. <source xml:lang="en">Immunol Cell Biol</source>. <year>2005</year>;<volume>83</volume>(<issue>2</issue>):<fpage>119</fpage>&#x02010;<lpage>128</lpage>. <pub-id pub-id-type="pmid">15748208</pub-id></mixed-citation></ref><ref id="irv12697-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="irv12697-cit-0091">
<string-name>
<surname>Skene</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Sutton</surname>
<given-names>P</given-names>
</string-name>. <article-title>Saponin&#x02010;adjuvanted particulate vaccines for clinical use</article-title>. <source xml:lang="en">Methods</source>. <year>2006</year>;<volume>40</volume>(<issue>1</issue>):<fpage>53</fpage>&#x02010;<lpage>59</lpage>.<pub-id pub-id-type="pmid">16997713</pub-id></mixed-citation></ref><ref id="irv12697-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="irv12697-cit-0092">
<string-name>
<surname>Dalsgaard</surname>
<given-names>K</given-names>
</string-name>. <article-title>Saponin adjuvants. III. Isolation of a substance from <italic>Quillaja saponaria</italic> Molina with adjuvant activity in foot&#x02010;and&#x02010;mouth disease vaccines</article-title>. <source xml:lang="en">Arch Gesamte Virusforsch</source>. <year>1974</year>;<volume>44</volume>(<issue>3</issue>):<fpage>243</fpage>&#x02013;<lpage>254</lpage>.<pub-id pub-id-type="pmid">4365900</pub-id></mixed-citation></ref><ref id="irv12697-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="irv12697-cit-0093">
<string-name>
<surname>Zhu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tuo</surname>
<given-names>W</given-names>
</string-name>. <article-title>QS&#x02010;21: a potent vaccine adjuvant</article-title>. <source xml:lang="en">Nat Prod Chem Res</source>. <year>2016</year>;<volume>3</volume>(<issue>4</issue>):<fpage>e113</fpage>.<pub-id pub-id-type="pmid">27213168</pub-id></mixed-citation></ref><ref id="irv12697-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="irv12697-cit-0094">
<string-name>
<surname>Rimmelzwaan</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Nieuwkoop</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Brandenburg</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM<sup>TM</sup> vaccines and conventional vaccines</article-title>. <source xml:lang="en">Vaccine</source>. <year>2000</year>;<volume>19</volume>(<issue>9&#x02013;10</issue>):<fpage>1180</fpage>&#x02010;<lpage>1187</lpage>.<pub-id pub-id-type="pmid">11137255</pub-id></mixed-citation></ref><ref id="irv12697-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="irv12697-cit-0095">
<string-name>
<surname>Sambhara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kurichh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Miranda</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU&#x02010;ISCOM vaccine in mice requires both cytotoxic T&#x02010;lymphocyte and macrophage function</article-title>. <source xml:lang="en">Cell Immunol</source>. <year>2001</year>;<volume>211</volume>(<issue>2</issue>):<fpage>143</fpage>&#x02010;<lpage>153</lpage>.<pub-id pub-id-type="pmid">11591118</pub-id></mixed-citation></ref><ref id="irv12697-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="irv12697-cit-0096">
<string-name>
<surname>L&#x000f6;vgren Bengtsson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Morein</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Osterhaus</surname>
<given-names>A</given-names>
</string-name>. <article-title>ISCOM technology&#x02010;based Matrix M<sup>TM</sup> adjuvant: success in future vaccines relies on formulation</article-title>. <source xml:lang="en">Expert Rev Vaccines</source>. <year>2011</year>;<volume>10</volume>(<issue>4</issue>):<fpage>401</fpage>&#x02010;<lpage>403</lpage>.<pub-id pub-id-type="pmid">21506635</pub-id></mixed-citation></ref><ref id="irv12697-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="irv12697-cit-0097">
<string-name>
<surname>Cox</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Madhun</surname>
<given-names>AS</given-names>
</string-name>, et al. <article-title>Evaluation of a virosomal H5N1 vaccine formulated with Matrix M<sup>TM</sup> adjuvant in a phase I clinical trial</article-title>. <source xml:lang="en">Vaccine</source>. <year>2011</year>;<volume>29</volume>(<issue>45</issue>):<fpage>8049</fpage>&#x02010;<lpage>8059</lpage>.<pub-id pub-id-type="pmid">21864624</pub-id></mixed-citation></ref><ref id="irv12697-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="irv12697-cit-0098">
<string-name>
<surname>Madhun</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Haaheim</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Nilsen</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Intramuscular Matrix&#x02010;M&#x02010;adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+cells and strong antibody responses in mice</article-title>. <source xml:lang="en">Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>52</issue>):<fpage>7367</fpage>&#x02010;<lpage>7376</lpage>.<pub-id pub-id-type="pmid">19781678</pub-id></mixed-citation></ref><ref id="irv12697-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="irv12697-cit-0099">
<string-name>
<surname>Pedersen</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Major</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Roseby</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Madhun</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Matrix&#x02010;M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model</article-title>. <source xml:lang="en">Influenza Other Respir Viruses</source>. <year>2011</year>;<volume>5</volume>(<issue>6</issue>):<fpage>426</fpage>&#x02010;<lpage>437</lpage>.<pub-id pub-id-type="pmid">21668670</pub-id></mixed-citation></ref><ref id="irv12697-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="irv12697-cit-0100">
<string-name>
<surname>Rasheed</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Sandhyarani</surname>
<given-names>N</given-names>
</string-name>. <article-title>Femtomolar level detection of BRCA1 gene using a gold nanoparticle labeled sandwich type DNA sensor</article-title>. <source xml:lang="en">Colloids Surf B Biointerfaces</source>. <year>2014</year>;<volume>117</volume>:<fpage>7</fpage>&#x02010;<lpage>13</lpage>.<pub-id pub-id-type="pmid">24607518</pub-id></mixed-citation></ref><ref id="irv12697-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="irv12697-cit-0101">
<string-name>
<surname>Lin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hamme</surname>
<given-names>AT</given-names>
</string-name>. <article-title>Gold nanoparticle labeling based ICP&#x02010;MS detection/measurement of bacteria, and their quantitative photothermal destruction</article-title>. <source xml:lang="en">J Mater Chem B</source>. <year>2015</year>;<volume>3</volume>(<issue>17</issue>):<fpage>3573</fpage>&#x02010;<lpage>3582</lpage>.<pub-id pub-id-type="pmid">26417447</pub-id></mixed-citation></ref><ref id="irv12697-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="irv12697-cit-0102">
<string-name>
<surname>Tao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ziemer</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Gill</surname>
<given-names>HS</given-names>
</string-name>. <article-title>Gold nanoparticle&#x02010;M2e conjugate coformulated with CpG induces protective immunity against influenza A virus</article-title>. <source xml:lang="en">Nanomedicine (Lond)</source>. <year>2014</year>;<volume>9</volume>(<issue>2</issue>):<fpage>237</fpage>&#x02010;<lpage>251</lpage>.<pub-id pub-id-type="pmid">23829488</pub-id></mixed-citation></ref><ref id="irv12697-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="irv12697-cit-0103">
<string-name>
<surname>Ingrole</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Tao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Tripathy</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Gill</surname>
<given-names>HS</given-names>
</string-name>. <article-title>Synthesis and immunogenicity assessment of elastin&#x02010;like polypeptide&#x02010;M2e construct as an influenza antigen</article-title>. <source xml:lang="en">Nano Life</source>. <year>2014</year>;<volume>4</volume>(<issue>2</issue>):<fpage>1450004</fpage>.<pub-id pub-id-type="pmid">25825595</pub-id></mixed-citation></ref><ref id="irv12697-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="irv12697-cit-0104">
<string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>BZ</given-names>
</string-name>. <article-title>Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity</article-title>. <source xml:lang="en">Nanomedicine</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>1349</fpage>&#x02010;<lpage>1360</lpage>.<pub-id pub-id-type="pmid">29649593</pub-id></mixed-citation></ref><ref id="irv12697-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="irv12697-cit-0105">
<string-name>
<surname>Vela&#x02010;Ramirez</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Boggiatto</surname>
<given-names>PM</given-names>
</string-name>, et al. <article-title>Safety and biocompatibility of carbohydrate&#x02010;functionalized polyanhydride nanoparticles</article-title>. <source xml:lang="en">AAPS J</source>. <year>2015</year>;<volume>17</volume>(<issue>1</issue>):<fpage>256</fpage>&#x02010;<lpage>267</lpage>.<pub-id pub-id-type="pmid">25421457</pub-id></mixed-citation></ref><ref id="irv12697-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="irv12697-cit-0106">
<string-name>
<surname>Jain</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>O'Hagan</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>M</given-names>
</string-name>. <article-title>The long&#x02010;term potential of biodegradable poly(lactideco&#x02010;glycolide) microparticles as the next&#x02010;generation vaccine adjuvant</article-title>. <source xml:lang="en">Expert Rev Vaccines</source>. <year>2011</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1731</fpage>&#x02010;<lpage>1742</lpage>.<pub-id pub-id-type="pmid">22085176</pub-id></mixed-citation></ref><ref id="irv12697-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="irv12697-cit-0107">
<string-name>
<surname>Pawar</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mangal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goswami</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jaganathan</surname>
<given-names>KS</given-names>
</string-name>. <article-title>Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: Effect of mucoadhesive coating on antigen uptake and immune adjuvant activity</article-title>. <source xml:lang="en">Eur J Pharm Biopharm</source>. <year>2013</year>;<volume>85</volume>(<issue>3, Part A</issue>):<fpage>550</fpage>&#x02013;<lpage>559</lpage>.<pub-id pub-id-type="pmid">23831265</pub-id></mixed-citation></ref><ref id="irv12697-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="irv12697-cit-0108">
<string-name>
<surname>Lynn</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Langer</surname>
<given-names>R</given-names>
</string-name>. <article-title>Degradable Poly(&#x003b2;&#x02010;amino esters): synthesis, characterization, and self&#x02010;assembly with plasmid DNA</article-title>. <source xml:lang="en">J Am Chem Soc</source>. <year>2000</year>;<volume>122</volume>(<issue>44</issue>):<fpage>10761</fpage>&#x02010;<lpage>10768</lpage>.</mixed-citation></ref><ref id="irv12697-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="irv12697-cit-0109">
<string-name>
<surname>Santos</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Carneiro</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>de Moura</surname>
<given-names>TR</given-names>
</string-name>, et al. <article-title>PLGA nanoparticles loaded with KMP&#x02010;11 stimulate innate immunity and induce the killing of <italic>Leishmania</italic>
</article-title>. <source xml:lang="en">Nanomedicine</source>. <year>2013</year>;<volume>9</volume>(<issue>7</issue>):<fpage>985</fpage>&#x02010;<lpage>995</lpage>.<pub-id pub-id-type="pmid">23603355</pub-id></mixed-citation></ref><ref id="irv12697-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="irv12697-cit-0110">
<string-name>
<surname>Thomas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rawat</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hope&#x02010;Weeks</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ahsan</surname>
<given-names>F</given-names>
</string-name>. <article-title>Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine</article-title>. <source xml:lang="en">Mol Pharm</source>. <year>2011</year>;<volume>8</volume>(<issue>2</issue>):<fpage>405</fpage>&#x02010;<lpage>415</lpage>. <pub-id pub-id-type="pmid">21189035</pub-id></mixed-citation></ref><ref id="irv12697-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="irv12697-cit-0111">
<string-name>
<surname>Tan</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Oral <italic>Helicobacter pylori</italic> vaccine&#x02010;encapsulated acid&#x02010;resistant HP55/PLGA nanoparticles promote immune protection</article-title>. <source xml:lang="en">Eur J Pharm Biopharm</source>. <year>2017</year>;<volume>111</volume>:<fpage>33</fpage>&#x02010;<lpage>43</lpage>.<pub-id pub-id-type="pmid">27865932</pub-id></mixed-citation></ref><ref id="irv12697-bib-0112"><label>112</label><mixed-citation publication-type="miscellaneous" id="irv12697-cit-0112">
<article-title>Vaccines Blood &#x00026; Biologics&#x02010;Featured Influenza Vaccine for the 2019&#x02013;2020 Season</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2019-2020-season">https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2019-2020-season</ext-link>. (accessed on 1 September 2019)</mixed-citation></ref><ref id="irv12697-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="irv12697-cit-0113">
<string-name>
<surname>Mou</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Q</given-names>
</string-name>. <article-title>Immune Responses Induced by Recombinant <italic>Bacillus Subtilis</italic> Expressing the Hemagglutinin Protein of H5N1 in chickens</article-title>. <source xml:lang="en">Sci Rep</source>. <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02010;<lpage>11</lpage>.<pub-id pub-id-type="pmid">28442746</pub-id></mixed-citation></ref><ref id="irv12697-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="irv12697-cit-0114">
<string-name>
<surname>Luo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mohan</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>BZ</given-names>
</string-name>. <article-title>Sequential Immunizations with heterosubtypic virus&#x02010;like particles elicit cross protection against divergent influenza A viruses in mice</article-title>. <source xml:lang="en">Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02010;<lpage>13</lpage>.<pub-id pub-id-type="pmid">29311646</pub-id></mixed-citation></ref><ref id="irv12697-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="irv12697-cit-0115">
<string-name>
<surname>Pillet</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aubin</surname>
<given-names>&#x000c9;</given-names>
</string-name>, <string-name>
<surname>Tr&#x000e9;panier</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A plant&#x02010;derived quadrivalent virus like particle influenza vaccine induces cross&#x02010;reactive antibody and T cell response in healthy adults</article-title>. <source xml:lang="en">Clin Immunol</source>. <year>2016</year>;<volume>168</volume>:<fpage>72</fpage>&#x02010;<lpage>87</lpage>.<pub-id pub-id-type="pmid">26987887</pub-id></mixed-citation></ref><ref id="irv12697-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="irv12697-cit-0116">
<string-name>
<surname>Pillet</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Couillard</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tr&#x000e9;panier</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Immunogenicity and safety of a quadrivalent plant&#x02010;derived virus like particle influenza vaccine candidate&#x02014;Two randomized Phase II clinical trials in 18 to 49 and &#x02265;50 years old adults</article-title>. <source xml:lang="en">PLoS One</source>. <year>2020</year>;<volume>14</volume>(<issue>6</issue>):<elocation-id>e0216533</elocation-id>. </mixed-citation></ref><ref id="irv12697-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="irv12697-cit-0117">
<string-name>
<surname>Barnier&#x02010;Quer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Elsharkawy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Romeijn</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kros</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jiskoot</surname>
<given-names>W</given-names>
</string-name>. <article-title>Adjuvant effect of cationic liposomes for subunit influenza vaccine: Influence of antigen loading method, cholesterol and immune modulators</article-title>. <source xml:lang="en">Pharmaceutics</source>. <year>2013</year>;<volume>5</volume>(<issue>3</issue>):<fpage>392</fpage>&#x02010;<lpage>410</lpage>.<pub-id pub-id-type="pmid">24300513</pub-id></mixed-citation></ref><ref id="irv12697-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="irv12697-cit-0118">
<string-name>
<surname>Herzog</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>K&#x000fc;nzi</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Eleven years of Inflexal&#x000ae; V&#x02014;a virosomal adjuvanted influenza vaccine</article-title>. <source xml:lang="en">Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>33</issue>):<fpage>4381</fpage>&#x02010;<lpage>4387</lpage>.<pub-id pub-id-type="pmid">19450630</pub-id></mixed-citation></ref></ref-list></back></article>